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Abst rac t 
Synthesis and characterization of oligonucleotides containing an 
(96-deoxyguanosine-alkyl-(96-deoxyguanosine interstrand cross-link 
Jason D. Booth 
Studies have shown that resistance to bifunctional alkylating agents used in the 
treatment of chronic myelogenous leukemia can result in diminished effectiveness of these 
therapeutics. To further understand this process we have developed clinically relevant models 
of cross-linked DNA duplexes to study the structure and repair of lesions induced by the 
bifunctional alkylating agents: busulfan and hepsulfam. To emulate the known 
deoxyguanosine-7V7-alkyl-iV7-deoxyguanosine lesion formed by hepsulfam and the 
unidentified lesion(s) formed by busulfan, we have designed three synthetic approaches 
leading to the synthesis of six stable deoxyguanosine dimers. General mono, bi and tripartite 
syntheses were developed for the preparation of 1,1 and l,3-deoxyguanosine-06-alkyl-<96-
deoxyguanosine cross-links employing 'fast-deprotecting' phenoxyacetyl protection at the N2 
position for facile removal. The 06-alkyl couplings are performed via a Mitsunobu reaction 
between a nucleoside and a mono-protected diol. The phosphoramidites of synthesized 
dimers were incorporated into one helical turn and 'sticky-end' DNA duplexes via solid-phase 
synthesis employing a DNA synthesizer. All duplexes were of defined structure and sequence 
for the purpose of further conformational analysis and enzymatic repair studies. Sequence 
composition was confirmed via enzymatic digestion and purity by subsequent HPLC analysis. 
A variety of methods including ultraviolet transition thermal denaturation (Tm), circular 
dichroism (CD) and gel electrophoretic studies were employed to characterize the cross-
linked duplexes. CD and Tm studies suggest little deformation from native B-form 
conformation for the hepsulfam mimics. Sufficient quantities of the mono and bipartate 
heptyl cross-linked duplexes were obtained for various structural studies with required 
quantities for biological investigations obtained for the monopartate synthesis. 
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Chapter 1 : Introduction 
1.0 Background 
Cancer is second in the developed world only to heart disease in the number of deaths 
that are caused. In spite of the enormous thrust of research to understand and treat cancer in 
its various forms, it remains one of the most frequent ailments in Western society. A 
central tenet of the problem is a fundamental lack of understanding into the mechanisms of 
initiation and cessation of the disease. Some of the most common medications employed 
are toxic to both healthy and cancerous cells. A severe limitation to the effectiveness of 
many therapeutics is the requirement to selectively kill neoplastic cells must be balanced 
against preserving healthy cells in the patient. This results in a limitation to effective 
treatment being the amount of damage that can be tolerated by normal cells. Unfortunately, 
many treatments commonly also present a latent risk of future complications due to the 
non-specific nature of lesions inflicted upon DNA in all cells.1 This presents the impetus to 
better understand the role of cellular repair mechanisms as it pertains to increasing the 
therapeutic window of existing anti-cancer treatments or the development of new 
medications possessing higher specificity. 
Molecular biology has come to the forefront as one of the most effective tools in our 
arsenal to discern enzymatic repair pathways critical to understanding the origins of the 
development of resistance to existing therapies. From this enormous body of research, 
many valuable insights have been gleaned into the mechanism of initiation of cancer and 
cellular repair mechanisms. The increased anti-tumour activity of Afunctional alkylating 
agents (BFAs) over mono-functional alkylating agents (MFAs) has been known for more 
than one half of a century.2 The toxicity that results from the ability to form an interstrand 
1 
cross-link (ICL) in DNA has made them some of the most commonly employed 
chemotherapeutic agents still in use.3' 4' 5 ' 6 The diminished toxicity of MFAs has been 
related to single strand breaks or damage caused to individual bases whereas BFA have 
been shown to induce double strand breaks.2 ICLs can also serve to act as an absolute 
barrier prohibiting strand separation thus arresting DNA transcription and/or replication 
leading to apoptosis and inhibition of tumour growth.5 
It is commonly held that alkylating agents are non-specific with respect to the cell-
cycle phase, occurring in both dividing and non-dividing cells.7 Alkylation of DNA has 
deleterious biological consequences during DNA replication. More specifically, ICL are 
highly toxic to proliferating cells due to their ability to induce mutations and chromosomal 
rearrangements causing gross chromosomal alterations such as double strand breaks or 
single strand gaps resulting in apoptosis.1'5'8 The ability of ICL agents to obstruct normal 
cellular metabolism has resultantly placed them among the most toxic sources of DNA 
damage. A survey of 234 genotoxic agents demonstrated that 12 of the 20 most toxic were 
BFAs capable of forming ICLs.9 In like fashion a single ICL can kill a repair-deficient 
bacteria or yeast cell,3 where about 20 can be lethal to mammalian cells that lack the ability 
to remove the cross-link.5 The acute toxicity of ICLs can be demonstrated by their potential 
to induce tumour formation in rodents where the TD50 (the total life time dose of 
carcinogen required to increase the probability of tumour formation to 50%) is 10-1000 fold 
less for cross-linking agents than for MFAs.1 In addition to exogenous sources of ICL 
agents such as psoralens present in many plants and cosmetics, endogenous agents can be 
T 1 A 
generated during lipid peroxidation such as malondialdehyde also forming ICL. ' The 
relevance of lipid peroxidation is not considered significant due to their low stability and 
2 
relatively low reactivity under physiological conditions.11'I2 The inherent toxicity that both 
exogenous and endogenous ICL agents pose to normal cellular metabolism has 
consequently led cells to necessarily develop mechanisms to repair these absolute blocks to 
strand separation in their DNA. 
To cope with the potentially lethal effects of ICLs, cells have evolved complex 
systems of genetic repair to detect and remove these deleterious lesions. More remains to 
be discovered about cellular recognition mechanisms if the origins of drug resistance are to 
be discovered. What is known is that ICLs can induce helical distortion such as unwinding 
or bending which is thought to be one of the primary sources of lesion recognition. 
Generalizations are difficult as the structures of ICL show a broad range of diversity which 
could affect the recognition of ICL lesions.3 Another possible means of ICL identification 
is the detection of a blockage in a replication fork or transcription.3 Whether resistance is 
acquired via exposure or is inherent to the organism, several pathways commonly are 
required to work in concert to repair or circumvent ICLs.3'7 
Broadly defined, drug resistance for BFAs can typically be described as the capacity 
to detect and repair ICL lesions in DNA caused by cytotoxic drugs. Currently, many 
patients that undergo treatment with these medications develop a resistance to existing 
chemotherapeutics resulting in a decreased efficacy of the drug. Resistance to drug 
regiments consists of a multifactorial combination of variables that are attributed, but not 
limited to, enhanced repair of DNA which is strongly correlated to the outcome of the 
individual patient.7'13 For example some contributing factors to poor response to therapies 
consist of a myriad of reasons from enhanced resistance via a number of repair pathways to 
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the response of the patient, the type of drug employed, cellular uptake, the strain of tumour 
cell treated and multiple unknown factors.3'7 
To address the importance of understanding the role of DNA damage in cancer 
formation and prevention, the study of the repair mechanisms of DNA is of paramount 
importance to discover new therapeutics that have the potential to act specifically and/or 
evade repair.5 Complicating the identification of trends in the study of repair systems is the 
growing consensus that different cross-links and in some cases different orientations of the 
same cross-link, are repaired in a different manner.5 It has been estimated that the most 
challenging obstacle to discern repair pathways is the existence of multiple overlapping and 
redundant mechanisms.5 Many repair studies have been performed on prokaryotic cells 
which have revealed valuable insights into DNA cross-link repair mechanisms however 
repair in eukaryotic cells is considerably more complex which is reflected in the increase in 
the number of proteins involved and the difference in the number of ICL that can be lethal 
to a cell. ' In addition to more complex repair systems in eukaryotic cells, a BFA must 
gain entry into the cell followed by access into the nucleus. A serious limitation to the 
study of DNA repair mechanisms towards ICL is the current lack of substrates of defined 
structure which can be addressed through synthesis of model sequences.14 
Due to the relative stability of thymine psoralen dimers when contrasted to the 
inherent instability of JV7-alkyl-2'-deoxyguanosine adducts which tend to depurinate leaving 
abasic sites, the majority of studies employing ICL DNA substrates of defined sequence 
and structure have focused on the use of psoralens (Scheme l.l).5'16 Significant aspects of 
ICL in mammalian cells are comparable to repair in bacteria and yeast,3 however multiple 
aspects of repair do not translate to eukaryotic systems despite a significant amount of 
4 
homology. Additionally, it is highly unlikely that psoralen adducted thymine repair 
mechanisms are identical to those employed to remove cross-links between iV7-2'-
deoxyguanosine adducts. This is supported by pre-clinical studies from Teicher, Frei and 
co-workers which has demonstrated that multiple cell lines generally exhibit little cross-
resistance to different BFAs.15 This serves to highlight the necessity of DNA segments of 
defined structure and sequence to allow for isolation of experimental variables involved in 
the repair process. 
Although it is unlikely that ICL agents can be developed that are not liable to cellular 
repair mechanisms, the potential exists to design systems that can better evade repair or 
possess higher specificity.7 Potentially with the identification of the enzymes involved 
small molecule inhibitors could be synthesized to selectively mitigate repair in tumour 
cells. The immediate challenge is to synthesize DNA duplexes comprised of stable mimics 
incorporated into defined sequences and with known structure to act as a diagnostic tool to 
probe the molecular mechanisms of repair. 
5 
Scheme 1.1 Formation of a stable [2 + 2] cycloaddition psoralen mono (lb, 2b) and cross-
linked (3b) adducts in DNA from UVA activation of a psoralen intercalator with specific 
affinity for d(TpA)2. Both furan and pyrone rings of psoralen react separately giving two 
possible products as only addition to the furan ring first results in a low enough barrier of 










1.1 Busulfan and Hepsulfam 
The first clinical usage of busulfan (BU) was reported over 40 years ago for the 
treatment of chronic mylogenous leukemia (CML).17 By contrast the first pre-clinical use 
1 Q 
of hepsulfam (HM) was published in 1988 as a replacement of BU in treatment in CML. 
BU and HM are both part of a class of drugs which contain polar sulfonic acid ester leaving 
groups (Figure 1.1). Both exert the majority of their toxicity through irreversible alkylation 
of DNA forming ICLs. HM being a derivative of BU, was designed to improve the 
antitumour efficacy of the parent compound by the introduction of a more polar leaving 
group.19 HM demonstrated increased efficacy against leukemia cell lines that were 
relatively resistant to BU.19,20 After decades both medications still find application as 
chemotherapeutic agents for the treatment of CML with the study of their repair 
mechanisms remaining an active area of research. 
o o o o 
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HsC^H^O^^NT^O^ I I ^CHs H z N ^ I I ^ O - ^ N T ^ O ^ H ^ N H z 
O U J 2 0 O u - l 5 0 
BU HM 
Figure 1.1 Structures of sulfonic acid ester cross-linking agents busulfan (BU) and 
hepsulfam (HM). 
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1.2 Origins and Mechanism of Action of Alkylating Agents 
DNA undergoes various types of damage as a result of alkylation which involves 
nucleophilic attack upon electrophilic atoms. It is generally observed that electrophiles 
preferentially add at ring and exocyclic nitrogens, and to a lesser extent exocyclic oxygens, 
resulting in alkylated or Schiff base derivatives. 
In vivo there are three major sources of alkylation which originate from exogenous 
") 1 
and endogenous sources. The first is endogenous enzymatic methylation in a sequence 
specific manner for control of various cellular processes that typically results in a relatively 
minor perturbation of the DNA helix structure. ' ' The second source of DNA alkyl 
lesions can be generated from endogenous compounds such as acrolein and 
malondialdehyde.3'21 Alkylation with these compounds can result in the formation of a 
MFA or BFA where the BFA can either form a cyclic adduct or an ICL.J The third 
mechanism of DNA alkylation involves direct attack of nucleobases on small electrophilic 
exogenous compounds such as nitrogen mustards, sulfonates, and nitroso compounds which 
are present in the environment as pollutants or employed as chemical warfare and 
chemotherapeutic agents.21 
BU and HM are BFAs belonging to the previously mentioned third class of alkylating 
agents containing two reactive sulfonic acid ester moieties at either end of a linear alkyl 
chain of four and seven carbons respectively producing two electrophilic carbon atoms at 
either end. Both BU and HM's primary mechanism of action to exert a cytotoxic effect is 
to prevent DNA strand separation thus precluding transcription and/or replication through 
the formation of a covalent bond between the drug and the A^-position of two 2'-
deoxyguanosines with no observed reactivity towards other nucleosides (Figure 1.2). It is 
8 
thought that the increased nucleophilicity of the JV -position can be attributed to high 
electron density produced by base stacking and charge transfer within duplex DNA.25 High 
nucleophilicity coupled with the N1 lone pair of electrons being freely accessible in the 
major groove could account in part for the observed selectivity. 
Figure 1.2 Representation of the major and minor grooves within B-form DNA as viewed 
at the base pairing level. Grooves are defined with respect to the glycosyl linkage of each 
base to its respective 2'-deoxyribose.26 
Cross-link formation through bifunctional alkylation of the major observed N -T-
deoxyguanosine adduct can arise either by reaction with two adjacent 2'-deoxyguanosines 
in the same DNA strand or with 2'-deoxyguanosines in opposite strands of the sequence. 
Initiation of cross-link formation occurs when one of the electrophilic a-carbons to the 
sulfonic acid ester of BU or HM undergoes a second order reaction leading to nucleophilic 
attack by DNA resulting in loss of the sulfonic acid ester moiety which is a good leaving 
group (Figure 1.3). This leads to formation of a covalent bond with the JV7-position where 
positive charge is dispersed throughout the heteroaromatic ring. With the first alkylation 
event in place, the 2'-deoxyguanosine mono-adduct can then react with a variety of 
nucleophilic compounds in the body undergoing a second nucleophilic attack due to the 
bifunctional nature of BU and HM. The second sulfonic acid ester can be hydrolyzed to an 
9 
alcohol rendering monofunctionality producing no further reaction. Alternatively, cross-
links can form between proteins or intracellular thiols resulting in linkages to DNA.19 A 
second 2'-deoxyguanosine on the same or opposite strand of DNA can also be alkylated 
resulting in the formation of an intra or interstrand cross-link respectively. 
| IN INM2 
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Figure 1.3 Proposed mechanisms of alkylation of 2'-deoxyguanosine by BU (n=l, R=CH3) 
and HM (n=4, R=NH2) followed by cross-linking of DNA or attack by a nucleophile 
24 (protein, water, or other biomolecule). 
Overall, the reactivity of methylating agents towards 2'-deoxyguanosine is well 
known. It has been shown that the A^-position of dG and backbone phosphate oxygens 
account for about 85% of all methylation products. Despite the major lesions formed by 
small electrophilic alkylators (including methansulfonic acid) being JV7-MedG and 
phosphate backbone adducts, some studies have correlated electrophilic alkylators' 
carcinogenicity with the number of minor 06-alkyldG and <94-alkyldT lesions formed.28'29 
Although not reported for BU or HM, potential remains to elicit a toxic effect through, not 
only iV7-alkyl-7V7 ICL formation, but also through more stable 06-2'-deoxyguanosine or (f-
2'-deoxythymine adducts. 
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1.3 Derivatization and Stability 
Medications that alkylate at the JV7-position such as BU and HM form unstable 
adducts which invariably decompose during purification. To prevent decomposition via a 
depurination mechanism which results in the loss of the actual cross-link itself leaving an 
abasic site, an alkaline treatment is required. The use of alkaline derivatization results in a 
formamidopyrimidine (FAPY) derivative of increased stability making purification 
possible. Base treatment can be performed with methods involving NaOH or piperidine 
methods, each having different mechanisms, conditions and thus outcomes. Treatment with 
NaOH at pH 13 at physiological temperature results in an addition of a hydroxide ion to the 
exposition of an iV7-alkyl-2'-deoxyguanosine resulting in a ring opening yielding FAPY 
which is more stable than the parent compound. This stability is demonstrated by 
experiments in the absence of base at elevated temperature (100°C), depurination 
approaches completion within three minutes whereas NaOH treated samples under identical 
conditions experience little decomposition.30 The piperidine treatment method relies on the 
strong nucleophilicity of the base to form an iminium ion (Figure 1.4). This results in 
elimination of the 2'-deoxyribose followed by the formation of a Schiff base which then 
causes strand breakage via ^-elimination of the phosphates which is not observed with 
NaOH to any significant degree.30 Neither method produces addition to, or decomposition 
of, non-alkylated 2'-deoxyguanosines.24 Furthermore, base treatment with temperature 
elevation can serve to act as confirmation of N -addition as the labile glycosidic bond of N -
adducts of purines have not been demonstrated to be stabilized by base and as such 
decompose at high temperature. ' ' Similarly the relatively stable glycosidic bonds of C 
adducts of purines have not displayed any increased stability or chemical modification by 
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base treatment versus neutral pH when heated. ' ' As such base stabilization of the 
glycosidic bond would not be expected for alkylations at positions other than the A^-atom. 
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Figure 1.4 Sequential addition of NaOH to ^-alkylated 2 '-deoxy guano sine to form both 
the N1 or TV9 FAPY derivatives of DNA. Subsequent displacement by piperidine catalyzes 
/^-elimination of both phosphates from the sugar.31'30 NaOH will only add to iV7-alkylated 
2'-deoxyguanosine whereas piperidine results in strand breakage at ^-alkylated positions 
aiding in the determination of the site of alkylation in short oligomers. A small population 
of adenines are also alkylated at N3 but they are unreactive towards piperidine and do not 
result in strand breakage. 
Elution patterns demonstrate the formidable challenges in separating ICL containing 
duplexes from parent duplexes.24 The potential to form linkages between RNA is possible 
but mention is largely absent from literature due to short lifetime of mRNA and tRNA 
within the cell with DNA being the major target of BFA to form an ICL. To determine the 
position of alkylation for HM, guanosine was treated with excess alkylating agent followed 
by RP-HPLC analysis.24 Isolation of ribonucleic acid derivatives was possible due to the 
increased stability to depurination as a result of the electron withdrawing nature of the 
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2'OH which destabilizes carbocation formation (Figure 1.5). Derivatization of N1-
guanosine adducts to FAPY analogues can be clearly discerned based on spectrometric 
experiments which consist of observing the reversibility of the UV signature as a function 
of increasing pH conditions and mass-spectral analysis.24 Under high pH conditions it is 
observed that the UV spectral signature of ^-alkylated guanosine undergoes an irreversible 
base-initiated transition in UV signature whereas guanosine UV spectra is completely 
reversible once brought back to neutral pH.36 This is accounted for by addition of a 
hydroxide ion to the C -position resulting in ring opening to yield the FAPY derivative 
which processes a prominent shoulder centered around 280nm and a bathochromic shift of 
the absorption peak of 2'-deoxyguanosine.24 The molecular weights of the derivatives can 
then be confirmed by mass spectral analysis. 
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Figure 1.5 Depurination of an alkylated 2'-deoxyguanosine and guanosine at the N -
position via a carbocation intermediate resulting in abasic sites in DNA and RNA. The 
presence of the 2'OH alcohol in ribose sugars greatly impedes the formation of the 
carbocation resulting a greatly diminished rate for the depurination reaction in RNA in 
contrast to DNA.30'31 
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1.4 Cross-link Position and Identification 
The connectivity and three dimensional shape of a segment of DNA containing an 
ICL is of considerable importance with respect to enzymatic recognition and repair. 
Determination of the site of adduction, the orientation of a cross-link, degree of bending 
and helical unwinding have as of yet unknown effects on recognition of and repair of an 
ICL. Confirmation of the aforementioned parameters can be performed in a variety of ways 
including chemical derivatization, BFA treatment of comparative sequences, and 
biophysical studies. 
More traditionally, identification of cross-link location has been performed via a 
variant of the Maxam-Gilbert reaction which relies on hydrolysis of a terminally P 
radiolabeled duplex (Figure 1.4). jV7-FAPY-2'-deoxyguanosine adducts are generated 
using piperidine inducing strand breakage at A^-adduct sites.30'31 Derivatized samples are 
then purified using polyacrylamide gel electrophoresis (PAGE) and compared to standards 
to elucidate major cleavage sites which are indicative of adduct formation at specific 
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sequences. 
Support for the regioselectivity of the HM was evidenced from reaction of 
oligonucleotides of identical molecular weight and identical net base composition 
containing exclusively 5'-GC-3' or 5'-GXC-3' (where X is any nucleotide) sequences 
separated by AT tracts.24 It was observed after RP-HPLC purification that individual 
fractions analyzed using denaturing PAGE of the 5'-GC-3' eluted as a single band. 
Different 5'-GXC-3' HPLC fractions eluted as two bands leading to the conclusion that 
HM reacts with 5'-GXC-3' sequences to produce ICL in the synthetic DNA studied (Figure 
1.6).24 Mass spectral analysis also displayed masses corresponding to a depurinated dimer 
14 
in the 5'-GXC-3' sequence. In contrast, it has been observed that BU tends to induce 
primarily DNA intrastrand cross-links whereas HM induces predominantly ICL. ' The 
exact orientation of lesion formed with BU remains unknown however it is thought that 
adducts between both strands remains the primary mechanism of cytotoxicity as in HM. 
5'-GXC-3' 5'-GC-3' 
36 35 34 33 32 31 36 35 34 33 32 31 
HPLC Fraction Number 
Figure 1.6 Denaturing PAGE comparing HPLC fractions from HM treated 
oligonucleotides. 
The extent of bending and helical unwinding induced by an ICL can be determined in 
a variety of ways. Conventionally, ligation experiments employing one-helical turn tracts 
have been employed to measure the shift in mobility via nondenaturing PAGE by an 
additive effect exaggerating the helical perturbation induced by a single ICL. The 
amplified distortion impedes mobility within the polyacrylamide gel against a standard 
acting as a measure of the bending angle. The change in mobility can then be used to 
calculate the bending angle induced by a single lesion in a one-helical turn segment using 
the empirical relationship developed by Koo and Crothers.39'40 This approach can be 
laborious as ligation conditions must be optimized often for each DNA duplex studied to 
prevent over or under ligation.38 Under ligation can result in chain lengths too short to 
observe a significant change in the bulk three-dimensional properties producing little 
15 
change in mobility. Over ligation can result in DNA that requires excessive run times with 
little resolution. 
More recently as higher field NMR instruments have been developed, 2D-experiments 
can be performed on short DNA duplexes of defined sequence. Most studies conducted on 
short one helical turn oligomers (11 to 13-mers) can be conducted at 500-600 MHz (*H 
basis), combining *H , 13C, and sometimes 31P experiments in conjunction with NOESY.41 
Many studies are performed via a comparative analysis of a control duplex which is 
compared to an adduct containing duplex.42"45 Backbone torsion angles can be discerned 
which can then used to develop a model consistent with the observed structural information. 
From NMR data the regioselectivity of a cross-link, the amount of helical unwinding and 
the degree of bending induced in the strand by a cross-link can be elucidated. Valuable 
insight is gleaned from bending and helical unwinding characteristics which have been 
deemed some of the most probable features allowing for enzymatic recognition of ICL and 
other DNA damage. 
X-ray crystallographic diffraction studies have proved their value from the time that 
Watson and Crick elucidated the double helical structure of DNA more than half of a 
century ago.46 Despite the long history of X-ray studies in nucleic acids NMR remains a 
more accessible and commonly used technique. Even with a pure sample, there remains a 
significant challenge to obtain a crystal of high quality allowing for meaningful resolution. 
Whether or not a sample will crystallize is highly sequence and environment dependent.47 
Additionally to obtain meaningful information, the DNA duplex containing an ICL must be 
of a single orientation (e.g. 1,3). Crystals of insufficient quality tend to result in low 
resolution diffraction leading to ambiguities in structural elucidation. The importance of 
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obtaining both NMR and X-ray data in establishing hydrogen bond structure remains as O -
MedG-dT mismatch pairs have been shown to give conflicting alignments from the liquid to 
crystalline state (Figure 1.7).21'43'48 The benefit remains that the high resolution of x-ray 
structures provides information to aid in the establishment of the 3-dimensional structure of 
a modified oligonucleotide. This information is inherently useful for more sophisticated 
studies involving repair enzymes. 
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Figure 1.7 Differing orientations of an (96-MedG-dT mismatch pair dependant upon the 
method of analysis in both solution (NMR) and crystalline (x-ray) states.2 
Conformational variability in FAPY derivatives from the clinically relevant N -adduct 
results in unknown variables which potentially affect molecular repair studies. Insights 
derived from repair studies may not translate to the clinically relevant lesion formed by 
BFAs. There are significant differences in stability and structure of rigid purine ring 
systems to FAPY derivatives which exist as a mixture of structural and rotational isomers. 
Despite a significant increase in stability with FAPY derivatives over the parent N -adducts, 
74 7 
FAPY are still unstable at room temperature. It has been demonstrated that iV -FAPY-2'-
deoxyguanosine adducts exist as mixture of structural forms with the formyl group located 
at the N1 or JV9 position (Figure 1.4).49"51 Further variability exists in the form of rotational 
isomers where the formyl group is either anti or syn. ' The altered ring system produces 
notably different structural properties from the parent adduct resulting in ambiguities as to 
the relevance of the recognition and repair studies. 
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1.5 The Effect of Tautomeric and Resonance Forms on Base-Pairing Geometry 
All four natural nucleobases possess tautomeric forms which are typically depicted in 
the more stable lactam form which is the basis for Watson-Crick (WC) bonding. Each 
structure can also be drawn in its respective enol tautomer for which non-standard base 
pairings can be shown.47 The pKa of the JV1-hydrogen atom of 2'-deoxyguanosine is ~9, as 
such a modest degree of ionization could exist at physiological pH. The N deprotonated 
form of 2'-deoxyguanosine has an altered hydrogen bonding pattern which corresponds to 
the pattern of an 06-alkylated dG (Figure 1.8). It is known that <96-alkylated 2'-
deoxyguanosine can lead to non-standard base pairing with dT which can result in dGdC -> 
dAdT transitions. 
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Figure 1.8 (A) Ionization of an A^7-alkyl-2'-deoxyguanosine and possible pairing of with 
cytosine52 (B) Base pairing of N1 and 06-alkylguanosine and wobble base pairing of with 
cytosine42 (C) Base pairing of JV7 and 06-alkylguanosine mismatch with thymine having B-
form geometry. 3 
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Evidence for the number of minor 06-alkyldG and 04-alkyldT lesions and not the 
total number of alkylations being the source of carcinogenicity can be derived from the 
ability of AGT to lower the number of mutations produced by an alkylating agent.28'29 
Studies with methylating agents such as procarbazine form a variety of adducts with O6-
MedG being among the most cytotoxic.53 These studies do not necessarily prove that an 
N -MedG adduct cannot be mutagenic however they do provide the impetus for 
investigation of the mutagenic or cytotoxic potential of O -alkyldG cross-links. NMR and 
X-ray studies also provide insight as to the potential geometry of the bonding structure 
around a 5'-GXC-3' ICL if base pairing at each site in a 1,3 orientation is treated as a 
mono-alkylation. Structural data also presents the opportunity to augment susceptibility to 
repair and the toxicity studies of <96-MedGdT base pairing. 
The possibility of the enol tautomer playing a significant role in dG-dT mismatch base 
pairing is still under debate. Both X-ray and NMR studies have been unable to find 
evidence for the existence of tautomerism.54 X-ray structures with dG-dT mismatches 
support wobble base pairing while the possibility exists for only one form crystallizing. 
' H NMR experiments can detect downfield protons but these resonances cannot confidently 
be used to determine hydrogen bonding patterns.47 Other studies using P NMR and 
similarities in NOESY spectra indicate dGdC, <96-MedG-dT,43 and 06-EtdG-dT44 
containing duplexes have B-form conformations of normal WC geometry. In contrast, 
<96-MedG-dC42 and <96-EtdGdC45 containing duplexes have spectra similar to dG-dT 
having wobble geometry at the lesion site.21 The wobble geometry of O -MedGdC and 
B-form conformation of 06-MedG-dT43 potentially has an impact on recognition and repair 
of both lesions. 
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The existence of a shift in the hydrogen bonding pattern of # -MedG has been 
suggested as a potential mechanism for mutagenesis with thymine.46'47'56'57 The presence of 
an N -adduct, although addition at a position not directly involved in hydrogen bonding, 
can disrupt normal WC base pairing motifs. It has been reported that iV7-MedG has only 
one exchangeable proton (Nl-H) that has a pKa ~ 7 which can result in the loss of a proton 
under physiological pH.56 A loss of the JV1-proton would result in a change to the hydrogen 
bonding pattern with the ^-position becoming a hydrogen bond acceptor (Figure 1.8). 
NMR characterization of duplexes containing a single Af7-MedG adduct have shown 
relatively little distortion from the parent conformation.58 Alkylation of 06-dG has 
similarly been shown to cause only a small conformational change to the helical 
conformation, as evidenced from torsion angles of the phosphate backbone. The small 
amount of distortion induced in both lesions suggests that the deprotonated N -MedG may 
make a significant contribution to the hydrogen bonding character for the Nl -position from 
a donor to an acceptor. Prevention of the traditional WC base pair alignment inducing 
similar minor distortions in the respective helices leave the potential for similar repair 
pathways due to a comparable amount and type of helical distortion induced. 
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It is unlikely that a duplex containing a BU or HM ICL at either the O or N -position 
would undergo an 06-alkyldG-dC transition to form an 6>6-alkyldG-dT mismatched base 
pairs. Mismatch base pair transitions (06-alkyldG-dC -> 06-alkyldG-dT) are typically the 
result of faulty polymerase incorporation in mono alkylations. BU and HM treated cells 
have a peak ICL formation after 12 hours21 as such mono-adducts would be present for 
times which could allow a polymerase induced mismatch transition to occur however this 
can be excepted to be a minor occurrence. A more likely impact on repair would occur 
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from a false recognition and attempted repair of the 06-alkyldG-dC lesion by mismatch 
repair (MMR) as the geometry more closely resembles a dGdT mismatch. 
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1.6 Resistance to Therapeutic Alkylating Agents - DNA Repair 
The mechanisms involved in drug resistance for chemotherapeutic agents such as BU 
and HM are a multifactorial combination of altered drug delivery and uptake, decreased 
drug activation, increased metabolic inactivation, active drug efflux, enhanced repair of 
DNA, and overlapping repair systems.59 The interplay between overlapping repair 
mechanisms can be seen in the therapeutic effect of methylating drugs and MMR activity 
which adds a clinically relevant dimension to AGT repair of 06-MedG. It has been shown 
in MMR deficient cell lines depleted of AGT with 06-benzylguanine (06-BG) results in a 
failure to sensitize cells to methylating agents. Clinically achievable concentrations of the 
methylating agent temozolomide produce cytotoxic effects only in MMR proficient cells 
with low AGT activity.60 The (96-alkylated dG adducts formed do not elicit a cytotoxic 
effect in the absence of MMR even if they are mutagenic.53 Cell lines that are AGT 
deficient or depleted and have normal MMR activity display heightened sensitivity to O -
alkylating agents.53'60 It is thought that this heightened sensitivity is the result of strand 
breakage induced by MMR recognition.60 Cell lines with high levels of both MMR and 
AGT exhibit drug resistance mainly, but not exclusively, through up-regulation of AGT 
expression.60 Exposure to methylating agents and 06-BG has been shown to favour 
development of AGT-independent mechanisms of resistance.60 As such, MMR mutations 
seem to override the AGT mechanism of resistance as a cell's failure to detect lesions may 
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attenuate their toxicity. If AGT is incapable of recognizing a BU or HM O -dG-alkyl-0 -
dG ICL the potential exists to identify alternate mechanisms of drug resistance involving 
lesion recognition by MMR. Minor (96-alkylation products of BU and HM, if present, may 
be critical in the development of drug resistance to BU and/or HM.29'53 
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Classically it is assumed that a cell with a gene that has been silenced which is 
involved in genetic repair would be less fit as the vigour of an organism is dependant on the 
maintenance of its genome. Several genes and enzymes that play a critical role in MMR 
have been identified for which many reviews are available.61"63 It is clear that loss of MMR 
results in destabilization of the genome and causes high mutation rates in coding and non-
coding regions.64'65 In a variety of human cancers, the loss of DNA MMR has been 
observed which leads to drug resistance.66"70 By impairing the ability of a cell to detect 
DNA damage, the ability to regulate cellular metabolism and initiate apoptosis is 
diminished. Apoptosis can also be attenuated indirectly by increasing the mutation rate 
throughout the genome. MMR-deficient cells have been reported to be resistant to a 
variety of chemotherapeutic agents that form ICLs3 including BU which has been 
demonstrated in clinical trials to induce a reduced response in vivo in tumour cells.53 
The importance of MMR in resistance to BU is in part due to MMR enzyme's ability 
to recognize and bind to various types of adducts in DNA as well as mismatches.53 As 
opposed to being a primary repair protein, MMR appears to be more involved in 
recognition of specific types of DNA damage.53 Although MMR does not appear to have 
the capacity to recognize O -MedG , it can however detect O -MedG-dT mispairing after 
incorporation from a replication cycle.72 The current model of MMR recognition for a O6-
MedG-dT mismatch involves excision of a small DNA segment around the mismatched 
thymine. Thymine is then reincorporated triggering another round of repair resulting in an 
infinite loop of repair and excision which eventually has the potential to result in a double 
strand break triggering apoptosis. This predicts that loss of MMR confers resistance to 
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06-alkylators as the cell does not attempt repair. This is further supported by the fact that 
chromosomal transfer reinstituting MMR function eliminates methylation tolerance.73 
The minor structural alteration of HM from BU results in differences in the 
mechanisms of decomposition which may account for some of the divergence in therapeutic 
effect once in the body.18 BU undergoes hydrolysis via nucleophilic attack by water to give 
4-methanesulfonyl-oxybutanol, which subsequently undergoes an intramolecular 
displacement to yield tetrahydrofuran and methanesulfonic acid. In contrast, no evidence 
of such an intramolecular mechanism has been observed with HM.75 Instead, HM formed 
the intermediate 1,7-heptanemonoylsulfamic acid ester prior to complete hydrolysis to 1,7-
heptanediol.75 The lack of an intermolecular reaction with HM may help explain the 
differing pharmacokinetics and blood half-life of HM over BU. HM displays a 16 hour 
blood half-life versus 2-3 hours for BU which may also play a role in the observed 
difference of HM to show efficacy against BU resistant tumours. ' 
Overexpression of Glutathione-S'-transferase (GST) is regarded as a significant 
mechanism by which human tumour cells become resistant to chemotherapy with cytotoxic 
alkylating agents.78 Evidence also exists for increased sensitivity, and thus a possible 
mechanism of resistance development, for cells exposed to BU and HM under L-buthionine 
sulfoximine (BSO) depleted glutathione (GSH) conditions.19 Increased reactivity of BU 
over HM exists in the presence of GST with BU reacting with GSH to form a sulfonium ion 
metabolite.77'79 Early studies demonstrated HM was unable to react with GSH in either the 
absence or the presence of GST in blood using exposure times of only 1 hour in buffer and 
rat liver cytosol.19'80 Studies by Pacheco et. al. showed that peak HM induced ICL 
formation occurred after a 2 hour drug treatment followed with washing by centrifugation 
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and subsequent incubation for 12 hours followed by alkaline elution.18 Later studies by 
Davidson and Colvin using human as opposed to rat liver cytosol proteins, demonstrated 
HM forms conjugates with GSH when analyzed by mass spectrometry after a 2 hour drug 
exposure and a 12 hour incubation time.19 The multiple cell lines tested showed no 
correlation to HM with basal levels of GSH but did show increased sensitivity with BSO 
depletion of GST in a dose-dependant manner.19 BU's susceptibility to the GSH 
detoxification mechanism contrasts to the slower kinetics of HM to react with GST may be 
one dimension in the observed lack of drug cross-resistance of BU tolerant tumours.18'19 It 
remains that increased GST expression correlates positively with resistance to BU and to a 
lesser extent HM. 
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1.7 Direct Repair 
Currently more than 100 alkyltransferases are now known with crystal structures 
available for three of the enzymes (Figure 1.9).81'82 Human 06-alkylguanine-DNA 
alkyltransferase (AGT) directly reverses endogenous alkylation at the Opposition of 2'-
deoxyguanosine and 04-alkylthymine by transferring the 06-alkyl group to an active site 
cysteine (Cysl45) in an irreversible and stoichiometric reaction. ' The presence of a 
stable 06-2'-deoxyguano sine lesion is promutagenic, having the potential for mispairing 
with thymine giving rise to a transition mutation during replication (i.e. C->T transition 
resulting in GC-> AT after subsequent replication). It is unknown if the altered WC 
binding pattern of an (96-alkylated BU or HM ICL will result in mispairing if cellular 
attempts at repair employ lesion bypass. It has been demonstrated that both (GSH) and 
AGT confer resistance to alkylation chemotherapies making GSH and AGT active 
anticancer drug targets.19'85 
Figure 1.9. The three dimensional structure of AGT which is highly conserved in three 
kingdoms of life despite low sequence homology as revealed by a structural overlay of 
human (blue), E. coll (yellow), and P. kodakaraensis (purple) AGT enzymes. The active 
site cysteine, Asn-hinge, and arginine finger sidechains are also shown (sulphur yellow, 
oxygens red, nitrogens blue, carbons green). (B) is rotated 90° about the vertical axis 
relative to (A).82 
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The conformational and structural similarity between numerous AGT class enzymes 
have been well documented representing examples from 28 species as diverse as 
Eubacteria, Archaea, and Eukarya.82,84'85 Minor differences in structure have been reasoned 
to account for experimental results demonstrating varying rates of activity between 
different species.84 Variability in activities has not lead to evidence supporting differing 
mechanisms of action divergent from use of amino acid residues at non-conserved 
positions.86 Conformational studies using NMR data for the Escherichia coli Ada-C 
protein which aids in the repair of pre-mutagenic 06-alkylguanine lesions in DNA revealed 
only a small conformational change is experienced upon DNA binding.82 A similar DNA 
binding model also has been suggested for the human homologue from high resolution 
AGT crystal structures allowing for the use of Ada-C data for insight into human repair 
mechanisms (Figure 1.9).82'85 
Previous work has reported that BU does not elicit toxicity via alkylation at the O -
position in a way that can be influenced by AGT repair.6 This contrasts to stem cell lines 
with overexpression of GST, specifically the MGSTII form of GST, having increased 
survival rates when exposed in vivo to BU and HM.19'78 Studies employing 06-BG served 
to potentiate chloroethylating agent l,3-bis(2-chloroethyl)-l-nitrosourea (BCNU) toxicities 
f, 9.1 9.9. ft 
in normal human bone marrow cells.0'"'80 Similar treatment of cells with (T-BG left BU 
activity unaffected by depletion of AGT. ' ' This serves to further advance the claim that 
GST is the only known route for elimination of BU. Efficacy enhancement of 
chloroethylating agents in the presence of 06-BG but not BU leaves the potential for N1 
alkylation by BU or 06-alkylation that cannot be repaired by AGT.6'89 Given the homology 
in structure, it is likely that BU and HM share similar mechanisms of addition and repair. 
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The mechanism(s) of action for BU and repair mechanism(s) for BU or HM, to date remain 
unknown. 
Crystal structures of Ada-C and human AGT serve to provide a comprehensive 
framework for structure activity relationship studies (SAR) (Figure 1.10). It has been 
determined that the molecular basis for recognition is extrahelical flipping of the alkylated 
nucleobase into the binding pocket.82'85 Subsequent release of repaired DNA for 
methylated Oe-MedG lesions results when AGT undergoes a conformational change 
allowing dissociation from the repaired duplex.82,85 It has generally been found that 
substituents of increasing steric bulk at the O -position react with a decreasing rate. 
Adducts having decreased rates for repair by AGT due to increased steric bulk has 
suggested other repair systems such as nucleotide excision and MMR systems play an 
important role for the removal of derivatives other than 06-MedG lesions.62'63'90 To this 
end, studies have demonstrated that nucleotide excision repair (NER) seems to repair O -
ethyl-2'-deoxy guano sine lesions in vivo in Drosophila germ cells.90 
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Figure 1.10. DNA binding model of Ada-C with 06-MedG flipped into the active site 
through the opening between the recognition helix and wing. The orientation of the 
recognition helix of Ada-C with respect to the DNA is based on the CAP-DNA complex.91 
The colour scheme represents two categories of chemical shift movement observed for 
Ada-C backbone resonances upon DNA binding. Backbone regions of Ada-C most 
affected by DNA binding are coloured red, those less affected are coloured blue. 
Unaffected regions are coloured grey or white. Ada-C predominantly contacts a single 
strand of the duplex. Sidechains from residues showing potential interactions to the DNA 
backbone of the flipped strand are depicted. The exocyclic methyl group from <96-MedG is 
shown as a blue ball in the active site, juxtaposed with the side chain Cysl46 (blue).82 
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1.8 Synthesis of Modified Oligonucleotides for Repair Studies 
Nucleic acids, their derivatives and corresponding polymers are among some of the 
most studied groups of compounds known to man. Synthesis of nucleic acids has resulted 
in a significant number of drugs currently in late phase III clinical trails or on the market.91 
Interest in nucleic acids has not been limited to the synthesis of monomeric analogues. 
Many oligonucleotides form an emerging class of potent anti-viral agents and treatments for 
of a variety of cancers and inflammatory disorders. Automated oligonucleotide synthesis 
developed in the early 1980's by Ogilvie et. al. laid the ground work for the current ability 
to produce oligomers of DNA up to 150 nucleotides in length (Scheme 1.2). This access to 
specific sequences can then be amplified using PCR which has revolutionized the study of 
genetics. The study of cancer, being at its most fundamental level a genetic disease, has not 
been untouched by these developments. The study of molecular systems of repair is 
typically performed using segments of DNA which contain lesions from specific 
endogenous or exogenous damaging agents. To adequately study enzymatic DNA repair 
systems, sequences possessing modified bases having a single well defined modification at 
an individual site are required. 
Many enzymes display a high specificity for the identity of the substrate that is to be 
bound making many assays using modified oligonucleotides highly sensitive to unmodified 
impurities. One common problem in both cell-based and non-cell based assays is the 
presence of an unmodified oligonucleotide mixed even at small percent composition with 
modified oligomers.47 Enzymatic activity past a segment that does not have an ICL could 
lead to the ability of a cell to maintain cellular metabolism. This ability to bypass a site not 
containing a modification could lead to a poor correlation of an adduct to toxicity.94 With 
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defined structures more meaningful repair mechanism studies can be conducted. These 
deviations from clinically relevant DNA adducts highlight the need for access to sequences 
of defined structure and native base composition accessible through synthetic methods. 
This has prompted the development of various methods to produce oligonucleotides 
containing ICLs by three major approaches.47 
Scheme 1.2 Solid phase synthesis cycle employed for synthesis of DNA oligomers. The 
solid support is functionalized with a long chain alkyl linker terminally attached to a 
nucleoside. Cycle entry is started by the introduction of TCA resulting in detritylation. The 
free 5'-alcohol is then rinsed with solvent to remove traces of acid. Coupling is initiated by 
the addition of the next phosphoramidite in the presence of excess tetrazole resulting in the 
formation of the phosphite triester backbone. Capping is performed using acetic anhydride 
to arrest further chain growth of any unreacted free alcohols. Oxidation is carried out with 
iodine in the presence of water to form the phosphate backbone. Detritylation is then 
performed in an identical manner to cycle entry at which point another phase of coupling 
can be undertaken. Deprotection of all functional groups and removal from the solid 
support occurs after treatment with 1:3 ethanol/ammonia hydroxide overnight. 
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The classical method for alkylated oligonucleotide synthesis mirrors a cellular 
mutagenesis assay where small segments of native random sequence or chemically 
synthesized DNA of defined sequence are used.47 This approach is commonly employed 
for chemistries that are incompatible with phosphoramidites or deprotection conditions such 
7 47 7 
as N -guanyl adducts. Access to many clinically relevant structures, particularly N -
guanyl adducts, has been limited as the classical method suffers from multiple modification 
sites producing several types of damage. DNA is treated with excess alkylating agent 
resulting in a myriad of products of unknown structure and sequence comprised of 
monoalkylated, intrastrand and interstrand cross-linked sequences having low yields of the 
desired product (Figure 1.11).24'47 Isolation of the desired adduct is at best problematic as 
the complex mixture generated containing a variety of different and/or multiple lesions may 
be inseparable (Figure 1.3, 1.6).24 In fact, it has been observed in PAGE 
experiments/analysis of oligonucleotides having multiple alkylations elute as one band 
along with DNA control segments not treated with alkylating agent.24 These results suggest 
that BFA in a different regiopositions are inseparable, making the presence of artefacts 
highly probable. Further complicating the interpretation of subsequent enzymatic studies, 
an alkaline treatment is commonly required for iV7-adducts previous to purification to form 
the FAPY derivative to prevent decomposition through depurination. 
Figure 1.11. Post-synthetic strategy resulting in a mixture of mono-alkylation, intra and 
interstrand crosslink formation.24 
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The second method to prepare a DNA that is cross-linked occurs via a hybridization 
triggered reaction. One requirement of the hybridization triggered method is the 
requirement for compatibility with standard phosphoramidite and subsequent deprotection 
chemistries. This has the advantage of a limited number of side reactions that are 
constrained to a specific area of a given oligonucleotide which can be separated by HPLC 
with a reduced chance for artefacts. This efficient and direct approach combines traditional 
nucleic acid synthesis techniques in solution to prepare dimers with solid-phase synthesis to 
produce DNA sequences of defined structure containing the cross-links in a known 
orientation. This approach still suffers from the potential for minor contamination given the 
difficulty in separating oligomers with and without modifications. 
Covalent interstrand cross-linked segments of DNA that emulate lesions from BFA 
were first explored in the mid-1980's.95'96'97 Since then several covalently linked structures 
have been developed containing mitomycin C,98 psoralen,99'100 trimethylene1 ' or HM 
(Figure 1.1 & 1.12).40 Unlike working with BU or HM on synthetically relevant scales 
using excess alkylating agent, synthesis of cross-links from non-toxic precursors offers the 
comparative advantage of being very safe to work with. A dimer containing an ICL is 
synthesized and incorporated into a DNA chain via solid-phase synthesis. This approach 
has the advantage of far fewer side reactions thus giving a much simpler purification and 
greater confidence in the structure of the final DNA duplex. 
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Figure 1.12. Therapeutics which have been mimicked through covalently linked duplex 
DNA structures which have been synthesized to emulate lesions formed by BFAs. ' 
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1.9 Purification and Common Characterization Methods of Oligonucleotides 
Oligonucleotide purification is typically performed with a combination of HPLC and 
PAGE. Oligonucleotides are routinely purified with separations possible by HPLC using 
ion exchange chromatography using a low composition of ACN (-10%, not exceeding 
20%) and increasing NaCl gradient with longer oligomers eluting later than smaller ones.103 
Typically sufficient resolution can be achieved between oligomers up to 42 units in length 
differing by one nucleotide in length.103 Once fractions are collected and combined the 
desired oligomer can then be desalted by loading onto a disposable CI8 cartridge which is 
then eluted with water followed by methanol/water (1:1). The organic fractions containing 
the oligomer are collected and concentrated to yield the dried final compound. Individual 
nucleic acids and shorter oligonucleotides (up to 24-mers) can be separated using CI8 
reversed phase chromatography.47 In order to improve peak shape and resolution gradients 
employing methanol are generally superior to those used with ACN. Volatile aqueous 
buffers (e.g. ammonium acetate) are typically used allowing lyophilization. With both 
methods it is desirable to use elevated temperatures (maximum <10°C of the lowest boiling 
point solvent) to reduce self association of the oligomer resulting in departures from ideal 
elution characteristics. 
Purification via electrophoretic methods provides the highest level of sensitivity and 
resolution.47 Visualization using UV detection or intercalating staining techniques 
(STAINS-ALL™) can be used on oligonucleotides to enable a more sensitive level of 
detection with an increasing length of the oligonucleotide. Preparative PAGE is an 
alternative to HPLC separation however it is not commonly used as it suffers from lower 
recovery, lower mass loading, significantly longer run times, and is more labour intensive. 
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As in preparative HPLC, resolution decreases when performing preparative PAGE 
highlighting the need for verification of the purity prior to further steps. 
Nucleotide compositional analysis can be performed via a variety of techniques. 
Sequence composition can be performed via selective fragmentation creating a number 
collision induced products by ESI-TOF.104 In addition, an enzyme digestion using snake 
venom phosphodiesterase (SVPDE) followed by hydrolysis of phosphate bonds using calf 
intestine phosphatase is performed. The digested nucleosides are then analyzed by RP-
HPLC and relative integrations of the peaks eluting at known times are corrected for using 
the molar extinction coefficients. The corrected areas serve as a simple tool to ensure the 
observed ratio correlates with expected nucleic acid composition. This method suffers from 
a limited assessment of purity (-5-10% error) in the ratios that are present.47 This 
limitation can be offset by the enzymatic digestion having the potential to provide 
confirmation that the cross-linked dimer has remained intact throughout the synthetic and 
characterization processes. The intact dimer is evidenced by the presence of a single late 
eluting peak, no mono-adducts eluting at times intermediate to the monomer and dimer, and 
accurate unmodified nucleotide composition ratios. 
As is standard in the majority of modern chemistry, mass spectrometry (MS) is 
required to establish the molecular weight of a given oligonucleotide. Typically due to the 
large molecular weights of oligomers matrix assisted laser desorption/ionization - time of 
flight (MALDI-TOF) is frequently used for its ability to analyze molecules of high 
molecular weight. Properly calibrated MALDI-TOF instruments can deliver accuracy 
better than 1 part in 103 to 104 with the presence of a [M + H]+ and [M + Na]+ (or [M - H]") 
providing positive confirmation of oligonucleotide identity. 
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1.10 Biophysical Analysis of Oligonucleotides 
For approaching 40 years, circular dichroism (CD) has been used in the study of DNA 
conformation. The pervasiveness of the technique is in part due to its minimal sample 
requirements, the non-destructive nature of the procedure, the ability to study DNA 
conformations in solution, and the ease and sensitivity of such measurements.105 The value 
of CD spectra is apparent in their ability to distinguish between B-form or A-form 
conformations when compared to a standard. Deviations in the CD signature reveal 
qualitative information about possible alterations in conformation from native A or B-form 
structure of DNA. B-form structure can be characterized by the presence of a positive band 
at 280 nm and a negative band at 250 nm.47 The presence of an ICL and the amount of 
bending or helical unwinding induced can be qualitatively measured as indicated by a large 
or small perturbation from the control signature. Resultantly CD is commonly used to 
detect changes in secondary structure. 
The qualitative information derived from CD spectra can be used to ascertain some 
generalizations concerning specific regions of the UV spectrum as it relates to structure. 
The high variability in CD spectra is a result of the factorial nature of DNA sequence 
composition and the secondary and tertiary structures that result therein. Despite this 
variability, absorption profiles of a nucleic acid polymer are a function of nearest neighbour 
approximations at wavelengths above 210nm which can be used for compositional 
analysis.106 Illustrating the sequence dependency of CD, the magnitudes of the major CD 
bands above 230 nm are not greatly changed upon denaturation.105 Below 230 nm there can 
be a change in the magnitude around 220 nm of the band.105 The lower wavelength regions 
display little information beyond a signature pattern due to the number of bonds that begin 
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absorbing below 200 nm. For meaningful analysis to be determined any adduct addition, 
dehydration or other alterations must always be compared against a standard. 
Thermal melt (Tm) experiments are commonly used in DNA analysis to measure the 
change in stability of a given DNA duplex with respect to altered sequence or the presence 
of an adduct. The change in stability is measured as a plot of the normalized 
hyperchromicity at 260 nm against the temperature. As the temperature increases the 
annealed duplex begins to dissociate resulting in an increase in A260 referred to as 
hyperchromicity. Non-modified DNA duplexes produce sigmoidally shaped dissociation 
curves while less sigmoidal curves with large temperature range transitions generally 
indicate a disruption from normal WC base pairing in modified sequences. The 'melting 
point' of a given duplex is the point at which the duplex is annealed/dissociated or 
denatured in a 1:1 ratio as measured by a first derivative analysis of the Tm sigmoidal curve 
reaching a maximal rate of change at the inflection point. The observed hyperchromicity 
results in duplex DNA from the nucleobases being asymmetric with respect to electron 
density. When a nucleobase is excited with UV light a transition moment is created and the 
asymmetric bases couple with one another due to their van der Waals proximity. As the 
duplex dissociates under increasing temperature the base stacking becomes more 
disordered, diminishing the ability to transfer the induced transition dipole moment. This 
change in dipole transfer is observed as an increase in absorbance of ssDNA versus 
dsDNA. This change can be as great as 30% for some sequences. 
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Chapter 2: Research Objectives 
2.1 Design and synthetic strategy of 06-alkyl linked dG dimers and ICL DNA duplexes 
2'-Deoxyguanosine is the most common nucleobase to undergo modification under 
biological conditions.5'26 This biological sensitivity translates to susceptibility to 
decomposition or side reactions under a variety of commonly employed synthetic 
conditions. Distinct reactivity exists at multiple positions on the purine ring making 
chemistry with the heterocyclic base a formidable challenge.108 The presence of a 
tautomeric form in the molecule which shifts from a lactam (pKa^i ~ 9) to an enol form at 
high pH produces phenol type reactivity at the Opposition. This phenol character enables a 
wide variety of aromatic nucleophilic substitution reactions for the purpose of protection or 
alteration of the reactivity of positions on the aromatic ring.109 Replacement of the ex-
position oxygen typically requires extreme reaction conditions or that it be made a more 
effective leaving group. The TV1-position displays nucleophilicity being involved as a site of 
addition for multiple G-C cross-linking agents such as BCNU.6 The A^-exocyclic amine 
displays reactivity towards a variety drugs and is the basis for its need for protection, 
traditionally with isobutyryl chloride in pyridine.3'26 The N1 and A^-positions are 
nucleophilic displaying unique electronic and steric properties resulting in preferential 
addition of ribose to the A^-position. The exposition is an nucleophilic centre with a 
proton that is acidic enough to undergo exchange in deuterated solvents or be displaced by 
halogenating agents.110 In addition, the presence of primary and secondary alcohols on the 
sugar moiety allow for orthogonal protection and removal of protecting groups. Careful 
selection of the conditions utilized is critical to avoid a multitude of unwanted side 
reactions. 
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Synthetically prepared 2'-deoxyguanosine cross-links can utilize deaza-heterocyclic 
bases to limit side reactions97 or increase the stability of adducts formed at the ex-
position. The formation of 7-iodo-7-deaza-2'-deoxyguanosine requires multiple 
synthetic steps in contrast to the readily available natural analogues. It has also been found 
that attempts to alkylate C7-iodinated-7-deaza-2'-deoxyguanosine using palladium 
catalyzed reactions results in multiple side products.111 Palladium reactions on halogenated 
guanosines have been shown to proceed in relatively high yield using mono-yne reagents. 
The requirement for a bifunctional alkyl linker to install an ICL is suspected to be the 
source of unwanted side-reactions. Difficulties encountered in this lab with palladium 
catalyzed reactions resulting in multiple side reactions, arduous purifications and 
exceptionally low yields led us to synthesize a cross-linked dimer via alternative methods. 
Multiple alkylating agents display selectivity for either TV7 or O6 with several 
alkylating at both positions.90'112 For example, HM has been shown to form a number of 
^-alkylated products with 2'-deoxyguanosine including l,7-bis(guanyl)heptane. The 
synthesis of DNA duplexes containing chemically stable structural mimics presents the 
possibility for a method to elucidate the enzymes involved in repair of an ICL that links two 
2'-deoxyguanosine residues between the strands. The orientation of the O of 2'-
deoxyguanosine in B-form DNA is such that the lone pair of electrons on the oxygen 
protrudes prominently into the major groove providing free access to small electrophilic 
alkylators such as HM (Figure 1.1). 
Additionally it is known that stable <96-2'-deoxyguanosine lesions are produced by a 
number of electrophilic alkylators and can lead to mispairing with thymine giving rise to a 
transcriptional mutation.82 A structural mimic can provide a conduit for the investigation of 
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the role of 06-alkylation for mismatch and direct repair studies. The design of an <96-alkyl-
O6 analogue for BU and HM will allow for the construction of DNA segments of defined 
structure and sequence (Scheme 2.1). This in turn allows for future studies to confirm or 
disprove O -alkyl addition as a mechanism of action or the role of direct repair in removal 
of O6 lesions. Further potential exists for our O6 ICL to act as a structural mimic for 
addition to the N7 position with BU and HM (Scheme 2.3). 
Scheme 2.1: Retrosynthetic pathway from (I) the dimer integrated into the DNA duplex 
(II) the dimer that is amenable to solid phase synthesis and finally (III) a bifunctional linear 
alkyl chain and 2'-deoxyguanosine building blocks used to synthesize the dimer. 
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Multiple methods exist for the alkylation of the O6 position of 2'-deoxyguanosine 
many of which require the replacement of the oxygen with a better leaving group, typically 
a halogen atom or a quaternary nitrogen (Scheme 2.2).109 The most common of these 
reactions involves nucleophilic substitution with alkoxides having chlorine 
functionalization of the O position allowing for incorporation of a number of 
heteroaromatic alcohols.109 Reaction conditions require reflux conditions in the presence of 
POCI3 followed by a reaction with an alkoxide.109 The chlorinated methodology has the 
disadvantage of being unfeasible for syntheses in which the alcohol to be coupled is either 
expensive or difficult to prepare as the alcohol serves as both reactant and solvent.10 
Alternatively use of 2-aminopurin-6-yl-trimethylamonium chloride circumvents the need 
for the alkoxides as the solvent and provides a better leaving group. The disadvantage is 
that another synthetic step is required under harshly basic conditions using sodium 
hydride.109 Both approaches are only compatible with the purine ring system requiring 
subsequent addition of the 2'-deoxyribose.109 Syntheses that manage to overcome poor 
anomeric addition selectivity frequently require a sterically bulky adduct at the O -
position.113 This would preclude the ability for placement of an O -linkage prior to 
placement of the sugar moiety. Many 06-alkylation routes employ conditions that would 
quickly remove protecting groups commonly present in solid-phase oligonucleotide 
synthesis. Use of the Mitsunobu reaction was explored due to its exceptionally mild 
conditions, compatibility with all protecting groups employed in solid-phase 
oligonucleotide synthesis, minimal side reactions, and direct route to the desired alkyl 
linker for the synthesis of II in Scheme 2.1.115"117 
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Conditions: a) P0C13, iV.iV-diethylaniline (Sato); b) POCI3, DMF (Igi and Hayashi); c) 
POCl3, ACN, Et3NMe+Cl" (Hanson); d) NMe3, r.t; e) DMAP, NaH, R-OH, 6(XC, DMSO; f) 
NaH, R-OH 
Scheme 2.3. Structure of BU (n=2) and HM (n=5) with suggested clinically relevant N7 
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This thesis will deal specifically with studies on the synthesis of 2'-deoxyguanosine-0 -
alkyl-06-2'-deoxyguanosine ICLs and their incorporation into one helical turn DNA 
duplexes of defined sequence and cross-link orientation. Use of traditional solution phase 
synthesis and solid phase chemistries that allows for ordered removal of various hydroxyl 
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protecting groups providing units of asymmetry in the final DNA duplexes will be 
discussed (Scheme 2.2). The monopartate strategy has one unit of asymmetry enabling the 
synthesis of directly opposed 1,1 mismatched duplexes in addition to 1,2 ICL duplexes 
which can be later incorporated into a DNA plasmid for general repair studies. Introduction 
of an additional unit of asymmetry in the bipartate scheme allows synthesized duplexes to 
adopt the clinically relevant staggered 1,3-orientation also allowing incorporation of 'sticky 
ends' for future plasmid incorporation studies to examine repair pathways. Furthermore, 
the tripartate approach allows for complete strand asymmetry within a duplex but likewise 
requires complete orthogonal protection at all of the alcohols on the 2'-deoxyribose 
moieties of the dimer with protecting groups amenable to solid phase synthesis. Duplexes 
synthesized in this manner can add nucleoside phosphoramidites in a sequential manner to 
synthesize four unique DNA chains around the ICL dimer. These duplexes provide DNA 
sequences of defined structure and sequence that will allow more systematic investigation 
into repair mechanisms that reduce the efficacy of bifunctional alkylating antineoplastic 
agents. 
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Scheme 2.4 Progressively increasing control over the sequence composition of each DNA 
duplex is a function of increasing asymmetry. The ability for selective deprotection of 
individual alcohol functionalities imparts the ability to grow nucleotide chains individually. 
Nucleotide chains circled are symmetrical to another nucleotide chains in the duplex 
centred on the ICL. 
Monopartate DMT-0 
Bipartate DMT-0 






































Chapter 3 : Results and Discussion 
3.1. Synthesis and Properties of the Dimers. 
Synthesis of the mono-, bi-, and tripartate dimers began with the introduction of the 
phenoxyacetyl group at the Apposition. It should be noted that the most common group for 
N2 position of 2'-deoxyguanosine is the isobutyryl group. Initial attempts to synthesize our 
desired duplex using the traditional isobutyryl protection were successful for the 06-cross-
linked dimer. Unfortunately at the final deprotection stage of the duplex the two isobutyryl 
groups were retained as shown by MALDI-TOF analysis of the oligomers.118 In an effort to 
use a more labile TV protecting group synthesis of 1 employed a modified Jones transient 
phenoxyacetyl (Pac) protection with a yield of 88% (Scheme 3.1).119 The crude product 
consisted of a mixture of starting material and product. Reduced temperature (0°C) and 
timing (20 min) of NH4OH/H2O desilylation was critical to optimized yields. Removal of 
pyridine via high vacuum of the crude material greatly aided the successive liquid-liquid 
extractions (CH2CI2/H2O) which eliminated nearly all traces of starting material. 
Optimized yields of the more labile N2-phenoxyacetyl group were comparable to that of the 
traditional isobutyryl method despite the increased sensitivity to base. Subsequent 
tritylation of 1 proceeded to form 2 in high yields (88%) after quenching of the reaction 
mixture with stoichiometric amounts of NH4OH in methanol. Base treatment permitted 
neutralization of HC1 and consequently removal of pyridine by rotary evaporation prior to 
aqueous work-up of the organic phase. Overnight removal of pyridine by high vacuum also 
greatly aided purification by flash chromatography. 
Initially allyl 1-benzotriazolyl carbonate (Alloc-OBt) was commercially available 
however during the course of this work another route for allyl carbonate protection had to 
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be explored. Attempts to use allyl-chloroformate in the presence of triethylamine (TEA) 
for 3'-allylation produced exclusively decomposition products. Alloc-OBt was synthesized 
via a condensation reaction with allyl-chloroformate and 1-benzotriazole producing highly 
favourable results (85%).I22 During Alloc-OBt recrystallization, removal of excess TEA 
and other side products proved unsatisfactory in our hands based on procedures described 
from literature methods.120 Yields were low (>25-40%) and NMR revealed only a partial 
enrichment in purity of the crystals obtained versus the mother liquor with the resulting 
product in lower than expected yields. A simple chromatography using CH2CI2 on 
dehydrated silica gel was sufficient to produce Alloc-OBt in greater than 95% purity in 
comparable yields to that of the previously reported recrystallization method. ' 
Subsequent reactions with chromatographed Alloc-OBt proceeded efficiently producing 3 
in higher yields (>85%) in contrast to (<65%) the recrystallized material. 
Scheme 3.1 Synthesis of 5a (butyl, n =2) and 5b (heptyl, n = 5) monoalkylated 2'-
deoxyguanosine 
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Conditions: (i) 1) TMS-C1, pyridine, 0°C, 30 min, 2) Pac-Cl, Pyridine, 3-4 hours, 3) 
NH4OH/H20 (1:1), 0°C, 20 min, (ii) DMT-C1, Pyridine, 12 hours, (iii) Alloc-OBt, 
CH2Cl2/pyridine (9:1), 12 hours, (iv) 4-(tert-butyldiphenylsiloxy) butanol or l-(tert-
butyldiphenylsiloxy) heptanol (1.1 eqv.), triphenylphosphine (1.25 eqv.), DIAD (1.2 eqv.) 
(v) TBAF (1M in THF). 
3.1.1 Monopartate dimer synthesis 
It is difficult to imagine a more efficient method of dimer formation than by a direct 
alkylation using two equivalents of the fully protected monomer and one equivalent of the 
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bifunctional linear alkyl chain. Alkylation using Mitsunobu methodology at the (^-position 
was first reported by Pfleiderer. ' Mitsunobu coupling using 1,4-butanediol and two 
equivalents of 3 was attempted yielding only 3 and spent Mitsunobu reagents. It is thought 
that the 1,4-butanediol underwent an internal cyclization to produce tetrahydrofuran due the 
same tendency of BU under biological conditions.74 A mono-protected diol strategy was 
then employed for the synthesis of 4a and 4b which was optimal with slight (1.05-1.1 eqv.) 
excess of mono-silylated diol producing near quantitative addition. All reagents were 
added to the reaction mixture followed by drop-wise addition of 
diisopropylazidodicarboxylate (DIAD). Excess triphenylphosphine (PPI13) (1.1 eqv.) and 
DIAD (1.05 eqv.) ensured that all of the monosilylated alcohol remained in the 
acyloxyphosphonium ion form minimizing any homocoupling. A slight excess of PPI13 
over DIAD was used to limit DIAD anion additions to the Opposition.124 Work-up of the 
organic phase followed by flash chromatography with a short column on the crude mixture 
(sample:silica, 1:3, w/w) loaded in dichloromethane (DCM) and eluted with hexanes results 
in nearly all of the product and non-polar reaction components being eluted in the first 
fraction leaving the majority of triphenylphosphine oxide on the column as confirmed by 
thin layer chromatography (TLC). It was also observed that solvation in EtiO after 
purification resulted in selective precipitation of residual triphenylphosphine oxide 
contaminant for 4b (61.9%) and to a lesser extent 4a (78.9%), which was not successful on 
the crude mixture. Facile removal of the TBDPS group was performed using TBAF in THF 
to give 5a (70.3%) and 5b (89.6%) with flash chromatography allowing for the complete 
removal of any residual triphenylphosphine oxide contaminant. 
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Syntheses of monopartate dimers 6a (53.1%) and 6b (66.3%) (Scheme 3.2) were 
accomplished via a second Mitsunobu reaction of the 5a or 5b with a slight excess of 
3. ' Separations using various solvent compositions were attempted with 
ethylacetate/hexanes providing reasonable separation from all side products. The two alloc 
protecting groups of 6a and 6b were then removed using 5 mol% of 
tetrakis(triphenylphosphine) palladium (0) (Pd(PPli3)4) and 4 equivalents of a stock solution 
of n-butylamine and formic acid (1:1) to produce 7a (84.5%) and 7b (77.1%) after work-up 
and flash chromatography.120'121 Sample 7a was stored at -20°C for future use. 
Scheme 3.2. Synthetic strategy for compound 7a (n=l) and 8b (n=4). 
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Conditions: (i) 3 (1.01 eqv.), triphenylphosphine (1.25 eqv.), DIAD (1.2 eqv.), 1 hour (ii) 
Pd(PPh3)4 (5 mol%), PPh3 (0.25 eqv.), «-butylamine/formic acid (1:1, 4.0 eqv.), THF, 20 
min., (iii) diispropylammonium tetrazolide (3.4 eqv.), /?-2-cyanoethyl-jV,./V,./V',Af'-
tetraisopropylphosphane (3.5 eqv), THF, 30 min. 
NMR analysis of 7b prior to reaction was useful for determination of the moisture 
content of the sample as indicated by a singlet at 2.84 ppm in acetone-^. Once rigorously 
dried 7b was solvated in anhydrous DCM followed by the addition of 
diisopropylammonium tetrazolide (3.4 eqv) then the atmosphere was exchanged with argon. 
Using a 1 mL disposable syringe, p-2-cyanoethyl-A^,A^,iV'^V'-tetraisopropylphosphane agent 
(3.5 eqv.) was measured by volume and added over 30 seconds to a vigorously stirred 
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reaction mixture. Reaction progress was monitored by the visual formation of a white 
precipitate and the appearance of three diastereomeric phosphoramidite spots on TLC 
signalling complete consumption of the starting material. The reaction was quenched using 
5% NaHCC>3 (aq) followed by a brief work-up with the organic phase dried over Na2S04 
(MgS04 is slightly acidic) followed by immediate solvent rotary evaporation. The sample 
was purified via a hexanes precipitation from a minimum amount of DCM to yield an off-
white solid 8b (58.6%) which was sealed and stored at -20°C for use in solid phase 
synthesis. It should be noted that 8b is extremely acid and heat sensitive. Typically 
compounds were stored as the free alcohols and the final solution phase phosphitylation 
reaction performed as close as possible to the date of solid phase synthesis. 
3.1.2 Bipartate dimer synthesis 
Progress to the bipartate synthesis of a more asymmetric dimer allows synthesis of the 
clinically relevant lesion but requires a labile 3'-protecting group that does not allow for 
removal of both the allylcarbonate and 5'-Odimethoxytrityl (DMT) groups during 
deprotection. The ^-butyldimethylsilyl (TBS) protecting group is well established in 
nucleoside chemistry. Silylation of 2 with imidazole (6.0 eqv.) followed by TBS-C1 (3.0 
eqv.) in dimethylformamide (DMF) overnight afforded 9 (83.2%) after aqueous work-up 
and flash chromatography (Scheme 3.3). Compound 9 displays a lower polarity than 3 
eluting at approximately 20% lower ethylacetate (EtOAc) composition. 






2 9 (83.2%) 
Conditions: (i) TBS-C1, imidazole, DMF, 16 hours. 
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With both fully protected 2'-deoxyguanosine monomers in hand a second Mitsunobu 
reaction was performed to yield 10a and 10b (Scheme 3.4). Stoichiometric quantities of 
each monomer were critical to achieving maximal yields (10a, 62.9%; 10b, 71.8%) and the 
most straightforward purification. Subsequent treatment of 10a and 10b with 
tetrabutylammonium fluoride (TBAF, 1M) in tetrahydrofuran (THF) followed by 
purification was performed to give the pre-monoamidite dimers 11a and l ib (68.5 and 
71.1% respectively). Once again the samples were rigorously dried prior to 
phosphitylation. Using the more reactive ./V,iV-diisopropylamino cyanoethyl 
phosphoramidic chloride (1.5 eqv.) with DIPEA (2.0 eqv.) offered the advantage of using 
less equivalents of reactants with shorter reaction times.131'132 The reaction was quenched 
when the starting material was consumed and two diastereoisomers were visible by TLC. 
The phosphoramidite work-up was brief with drying over Na2SC>4 followed by immediate 
solvent rotary evaporation. The samples were purified by hexanes precipitation from a 
minimum amount of DCM to yield off-white solids 12a and 12b (88.3% and 97%) yields) 
and the samples sealed and stored at -20°C. Later solid phase synthesis experiments with 
12b to generate test oligonucleotides produced lower yields after overnight deprotection of 
the allyl carbonate protecting group. This prompted removal of the allyl carbonate from 
10b via previously higher yielding 'solution phase' chemistry leaving the TBS group to 
generate 13 (76.0% yield) after aqueous work-up and flash chromatography (Scheme 3.5). 
Compound 13 was then phosphitylated using JV.JV'-diisopropylamino cyanoethyl 
phosphoramidic chloride (1.5 eqv.) with DIPEA (2.0 eqv.) yielding 14 (86.3% yield) from a 
hexanes precipitation. 
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Scheme 3.4. Strategy for the bipartate synthesis of 12a (n=l) and 12b (n=4). 
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i =H), 75.0%, 86.6% 
POCE), 88.3%, 97% 
Conditions: (i) 5a/5b (1.01 eqv.), PPh3 (1.25 eqv.), DIAD (1.2 eqv.), 1 hour (ii) TBAF, 
THF, 30 min., (iii) DIPEA (2.0 eqv.), AfiV'-diisopropylamino cyanoethyl phosphoramidic 
chloride (1.5 eqv), THF, 30 min. 




13(R = H), 76.0% 
10b ii I 
* 14 (R = POCE), 86.3% 
Conditions: (i) 10b, Pd(PPh3)4 (5mol%), PPh3 (0.25 eqv.), n-butylamine/formic acid (1:1, 
2.5 eqv.), THF, 20 min., (ii) DIPEA (1.7 eqv.), A^A^'-diisopropylamino cyanoethyl 
phosphoramidic chloride (1.5 eqv), THF, 30 min. 
3.1.3 Tripartate dimer synthesis 
To develop a completely asymmetric DNA duplex the use of orthogonal protection is 
required at all 2'-deoxyribose alcohol positions. Building on previous chemistry monomer 
5 was used and two additional protecting groups were chosen. The requirement for a 
sterically demanding group capable of direction to the primary 5'-alcohol led to use of t-
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butyldiphenylsilyl chloride (TBDPS-C1) in dilute reaction conditions to further promote 
regioselectivity. Compound 1 was treated with imidazole (4.0 eqv.) in DMF followed by 
addition of TBDPS-C1 (1.1 eqv.) in five increments over 30 minutes to generate 15 (72% 
yield) after aqueous work-up and flash chromatography (Scheme 3.6). The observed 
polarity of the TBDPS group was greatly diminished, as observed by flash chromatography, 
over the DMT group resulting in elution with less polar solvents. Additionally, it was 
observed that TBDPS-C1 showed a similar reactivity to DMT-C1 but a slightly lower 
selectivity towards primary versus secondary alcohols. Longer reaction times which 
allowed the reaction to progress to completion had to be balanced with an increase in the 
amount of depurinated product observed. 
Scheme 3.6. Synthesis of tripartate monomer 16. 
O O Q 
<7i 1 (J 1 ( 
OH OH O-Lev 
1 15,72.0% 
Conditions: (i) 1 (1.0 eqv.), TBDPS-C1 (1.2 eqv.), imidazole (4.0 eqv.), DMF, 16 hours (ii) 
levulinic acid (6.0 eqv.), DCC (3.5 eqv.), dioxane, 3 hours. 
Small-scale 'litmus tests' were performed with hydrazine, employed in the 
deprotection of the levulinyl group showing no decomposition of l ib . This suggested no 
decomposition would be observed with dimers tripartate protecting groups. Synthesis of 
the fully protected monomer 16 was performed using 15 which was solvated in dioxane 
followed by addition of a dicyclohexylcarbodimide (DCC, 3.5 eqv.) and a catalytic amount 
of dimethylaminopyridine (DMAP, 0.1 eqv.).125 Levulinic acid (6.0 eqv.) was added to the 
vigorously stirred reaction. The reaction mixture changed to dark-orange brown in colour 
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with a white precipitate suspended in solution which was filtered off and rinsed with a 
minimal amount of dioxane. Sample work-up was then performed on the organic phase 
followed by flash chromatography. The product 16 displayed very little difference in 
polarity from that of 15 however purification was nonetheless straightforward as very little 
starting material remained. 
Syntheses of the tripartate dimer 17 (Scheme 3.7) was accomplished via a second 
Mitsunobu reaction of 5 with a slight excess of 16. Separations using various solvent 
compositions were attempted with hexanes/ethylacetate providing reasonable separation 
from all side products. The alloc protecting group of 17 was then removed using 5 mol% of 
Pd(PPli3)4 and a stock solution of n-butylamine and formic acid (1:1) (4 eqv.) to produce 18 
(84.5%) after aqueous work-up and flash chromatography.120'121 The bulk amount of 
sample 18 was stored at -20°C for future use. A portion of 18 was rigorously dried and 
treated with JV,iV'-diisopropylamino cyanoethyl phosphoramidic chloride (3.0 eqv.) with 
DIPEA (3.4 eqv.) in THF. The reaction was complete when starting material was 
consumed and two diastereoisomers were visible by TLC. The aqueous phosphoramidite 
work-up was brief and dried over Na2S04 followed by immediate solvent rotary 
evaporation. The decision was then made to perform flash chromatography in light of the 
number of equivalents of reagents that were required to bring the reaction to completion 
and the orange colour of the reaction mixture. The sample was solvated in 
dichloromethane/hexanes (1:1) and loaded on top of the column. All solvents were doped 
with five drops of TEA for every 100 mL of eluent. In the first fraction a white precipitate 
was noticed to emerge, as such, the collection vial was immediately switched to fraction 
two. TLC revealed the solid in fraction two to be 19 and fraction one contained excess 
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phosphitylating agent. After elution of precipitated 19 normal chromatography followed to 
yield an off-white solid (58.3%) and the samples sealed and stored at -20°C. 




S b 17,70.4% iii ( 
^ 19,58.3% 
Conditions: (i) 5b (1.01 eqv.), 16 (1.0 eqv.), triphenylphosphine (1.25 eqv.), DIAD (1.2 
eqv.), 1 hour (ii) Pd(PPh3)4 (5mol%), PPh3 (0.25 eqv.), «-butylamine/formic acid (1:1, 4.0 
eqv.), THF, 20 min., (iii) DIPEA (1.7 eqv.), JV,JV'-diisopropylamino cyanoethyl 
phosphoramidic chloride (1.5 eqv), THF, 30 min. 
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3.2 Synthesis, Characterization, and Properties of Oligonucleotides. 
Solid-phase synthesis was performed on an Applied Biosystems 3400 DNA 
Synthesizer via standard methods using commercially available 3'- and 5'-0-2'-
deoxyphosphoramidites on a 1-umol scale for each duplex synthesized (Scheme 
0*7 1 07 1 7 A 
1.2). ' ' The use of 'fast-deprotecting' phenoxyacetyl protection on all dimers made it 
necessary to use phenoxyacetic anhydride in place of acetic anhydride as the capping 
7 • • 
reagent to prevent an undesired iV-acetylation displacement reaction at the N -position 
177 • 
observed during solid-phase oligonucleotide synthesis. Base sequence compositions 
were chosen to allow structural comparisons with previous studies on synthesized duplexes 
1 70 1 "37 
containing a variety of cross-links of defined structure and sequence. " Selection of two 
alternating dG-dC pairs at each end allows for higher stability in the duplex form favoured 
for NMR studies.132 
Synthesizer parameters were programmed for coupling in the 3'->5' direction for 
each respective phosphoramidite (15-20 eqv.) and tetrazole (45 eqv.). Standard coupling 
times (120 s) were used for 2'-deoxyphosphoramidites and extended couplings for dimer 
incorporations (600 s) and the nucleotide proceeding after dimer couplings (180 s) to 
reduce the likelihood of diminished yield due to steric influences. Sequences were typed 
into the DNA synthesizer method in a 5'->3' direction. It was verified that the sequence 
selected on the computer software was correctly transferred to the DNA synthesizer. The 
number of times a phosphoramidite was to be incorporated into a DNA chain was used to 
calculate the quantity of phosphoramidite to be placed on each respective line. ACN was 
dried over CaH2 and transferred via syringe to each 5 mL test tube which was then capped 
and lightly vortexed to dissolve each respective compound. After installation on the 
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synthesizer of all reagents bottles and sample lines were purged with solvent under argon 
atmosphere to ensure anhydrous conditions. A visual check of all solvents levels, argon gas 
level, and monitoring for leaks was then performed. 
Linear sequences were coupled to each respective dimer were followed by a capping 
step, then visual monitored for the presence of the orange trityl cation eluting from the 
column after treatment with trichloroacetic acid (TCA). With the trityl protecting group 
removed, normal 3 ' - ^ 5 ' direction chain growth is resumed. For sequences requiring 
deprotection of the 3'-alcohol after the dimer has been coupled, the use of y-O-T-
deoxyphosphoramidites were required to continue chain growth for the final segment. 
After addition of the last nucleotide, oligomers were removed from the solid support and 
deprotected via treatment with 1:3 ethanol/ammonium hydroxide (28%) at 55°C for 4 
hours. The crude oligonucleotides were then purified by strong anion exchange (SAX) 
HPLC (Table 3.1). Purified samples were desalted by absorbing each sample onto a 
SEPPAK (CI8) column followed by washing with deionized water (30 mL) to remove salts 
and desorbed using ACN (3 mL x 2). The desalted samples were then evaporated using 
vacuum centrifugation to yield a dried solid. 
Table 3.1. Standard SAX-HPLC method for separation of oligonucleotides using a Waters 






















































Solvent A: 1 M Tris-HCl (pH 7.8) /10% ACN / H20 (1:1:8) 
Solvent B: 1 M Tris-HCl (pH 7.8) /10% ACN /1.25 M NaCl (1:1:8) 
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Coupling of 3'-phosphitylated dimers to a deprotected 5'-alcohol of a linear chain 
were performed in an 'on-column' and 'off-column' manner. The on-column method had 
the advantage of all dimer couplings to the linear chains being automated under anhydrous 
and inert argon atmosphere. The on-column method however suffers an unavoidable loss by 
sending the unused phosphoramidite dimer, used to prime sample delivery lines, to waste. 
Employing the off-column method involves removal of the column containing the solid 
support from the DNA synthesizer followed by transfer to a screw cap microfuge tube. The 
solid support is then suspended in an ACN solution containing phosphoramidite dimer and 
tetrazole. The off-column method offers the advantage of using only the required 
equivalents of dimer but suffers the disadvantage of manual manipulations exposing the 
reaction to non-anhydrous conditions via atmospheric moisture. After reacting off-column 
samples for an hour, the solid support is then transferred back into DNA synthesizer 
columns and rinsed using a vacuum apparatus with ACN (30mL) followed by THF (30mL). 
After removing all reagents, supports bearing oligomers were placed in columns then 
reinstalled on the DNA synthesizer and all sample lines purged with anhydrous solvent 
under argon then re-primed with reagents. 
The most symmetrical oligonucleotide to be synthesized involved an on-column 
synthesis of a 1,1-mismatch one helical turn ICL duplex (Schemes 2.2 & 3.8). The 
incorporation of the bis-phosphoramidite 8b (8a was not prepared) using the monopartate 
strategy contained the same type of functional and protecting groups as nucleotide 
monomers used in oligonucleotide synthesis making it highly amenable to on-column 
procedures. The quantity of each phosphoramidite nucleotide was calculated and placed on 
each respective line in a test-tube (Table 3.2). Allowance was made for 250 uL of priming 
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volume with an additional 50 uL for each commercially available nucleotide to ensure 
adequate volume in the base of the sample test-tube. Dimer coupling parameters were 
optimized with respect to concentration and coupling times. Analytical SAX HPLC runs 
revealed the optimal concentration range observed for coupling was at 0.10 M (coupling 
time 600 s) to balance insufficient amounts of dimer with over concentration resulting in 
mono-addition. A significant amount of 20, the pentamer L-sequence product, was 
observed when 0.05 M concentrations of 8b were employed (Figure 3.1). Concentrations 
of 0.15 M resulted in a diminished amount of pentamer 20 and two major products. The 
first is 21 resulting from mono-coupling of 8b to the linear oligonucleotide chain to yield a 
Y-like 17-mer. The second is the fully cross-linked duplex 22 which was easily separated 
by SAX HPLC from 20 and 21. The final yield of the cross-linked duplex 22 after 
purification and desalting was 12.6% (27.2 od units from a 1 umol scale synthesis). PAGE 
studies were used as a confirmation of purity of the final purified duplex 22 (Figure 3.2). 
Table 3.2. Calculated quantities required for solid-phase synthesis of ICL duplex 22 using 




















































































































Conditions: (i) The addition of 8b, (ii) continued chain growth with 3'-0-2'-
deoxyphosphoramidites, (iii) final detritylation using TCA followed by removal from the 
DNA synthesizer with subsequent cleavage from the solid-support and deprotection using 
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Figure 3.1 Analytical chromatograms using SAX HPLC of (A) the crude synthesis 
products of duplex 22 and (B) final purified product. 
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XL,, 
Figure 3.2 Analysis of purified oligonucleotide duplex 22 using denaturing 
PAGE (20 %) at room temperature. 
Compositional analysis of the cross-linked duplex 22 was performed by enzymatic 
digestion with SVPDE and calf intestine phosphatase followed by analysis of the 
nucleosides via RP-HPLC (CI8) as described previously14 as well as MALDI-TOF MS. 
An HPLC chromatogram shows the first four peaks elute using a gradient with retention 
times corresponding to dC, dG, dT, and dA standards (Figure 3.3, Table 3.3). The final 
peak at 25.4 min coelutes with a completely deprotected standard of dimer 8b. The ratio of 
the peak areas agrees with the nucleotide composition of the cross-linked oligonucleotide 
22 (Table 3.4). MALDI-TOF analysis of 22 indicated a molecular weight of 6806.9 
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Figure 3.3: Analysis of a snake venom phosphodiesterase and calf intestinal phosphatase 
digest using a Waters 1525 pump and 2487 detector using a Symmetry CI8 (4.6 x 150mm, 
5 urn) column. 
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Table 3.3. Standard HPLC method for separation of oligonucleotides using a Waters 1525 
















































Solvent A: 50mM Na2HP04 (pH 5.8) / 2% ACN / H20 
Solvent B: 50mM Na2HP04 (pH 5.8) / 50% ACN / H20 
Table 3.4 Nucleoside composition ratios corrected for molar extinction coefficients and 



























A variety of methods including ultraviolet transition Tm, CD, and gel electrophoretic 
mobility studies were employed to characterize synthesized duplexes. Deviations from the 
WC control duplex (24) dissociation temperatures are the result of primarily two effects 
giving an indication as to the effect of modifications on duplex stability. Entropic 
stabilization in 22 is observed as the two strands have less rotational degrees of freedom 
remaining unimolecular when fully denatured. Destabilization from the alteration to 
normal WC base pairing induced by the presence of an ICL or mismatched 2'-
deoxyguanosine bases (23, 1,1-mismatched (5'-dCGAAAGTTTCG)2) also serves to 
decrease dissociation temperatures. A sigmoidal denaturation curve qualitatively similar in 
shape to the 24 was exhibited for 22 (Figure 3.4). First derivative analysis of Tm plots 
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indicates dissociation temperatures of 35°C for duplex 23, 46°C for duplex 24, and 58°C for 
duplex 22. The presence of a mismatch in 23 resulted in a broadening of the sigmoidal 
curve as the duplex dissociated over a larger temperature range as evidenced by a 
diminished slope. 
0.30 , , 
Temperature (°C) 
Figure 3.4. UV thermal denaturation profile (A0.5°C/min) of the cross-linked (22), non-
cross-linked mismatch control duplex (23) (5'-dCGAAAGTTTCG)2, and non-cross-linked 
control (24) duplexes. 
The degree of hyperchromicity is similar at equivalent concentrations for 22 and 24. 
Duplex 23 possesses minimally diminished hyperchromicity possibly due to dG-dG 
mismatches being well tolerated resulting in little disruption in base-stacking interactions. 
The similarity in the magnitude of hyperchromicity for 22 and 24 suggests the disorder 
induced by the dG-dG mismatching may be balanced by the order conferred by the ICL. 
The forced proximity due to the unimolecular nature of 22 potentially maintains a degree of 
dipole transfer between bases at the site of the ICL accounting for the similarity in 
hyperchromicity and higher dissociation temperatures. 
62 
The CD spectra of 22, 23, and 24 duplexes are displayed in Figure 3.5. These spectra 
were recorded at 5°C where only the annealed form exists as evidenced from Tm data. The 
control duplex 24 exhibits a spectrum consistent with the signature of natural B-form DNA 
having a maximum at 284 nm, a minimum at 253 nm, and a crossover at 270 nm. The CD 
spectrum of duplexes 22 and 23 display a high degree of similarity with the general shape 
of 24, each having a relatively sharp positive band with maxima at 283 nm and 284 nm 
respectively. Crossover points for all three duplexes are identical at 270 nm. The molar 
ellipticity of 22 observed in the minima area centered on 255 nm has an identical shape 
however it displays 1.6 times greater molar ellipticity than that of 24. This is contrasted in 
the maxima area for 22 centered on 283 nm being 0.7 times less than the 24. This could 
result from subtle changes in stacking interactions of the bases at or near the site of the 
ICL.129 At lower wavelength duplex 23 displays a deviation from the signature pattern 
exhibited by the 24 having slight shoulder at 250 nm and a shift of the minima to 259 nm. 
There is overall lower amplitude of the 23 sequence in all regions compared to the 24. The 
observed relative difference of 23 from the 24 is 0.42 times in the maxima region and 0.57 
times in the minima region. This may be a result of the slight distortion of the duplex 
expected from the presumed wobble dG-dG base pair. The overall signature similarity of 
both 23 and 22 to that of 24 suggest no major structural change is induced. Observed 
patterns also indicate a minimal amount of helical distortion induced from the 7 carbon 
linker, closely approximating native form DNA. 
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Figure 3.5. CD profile of the cross-linked oligonucleotide 22, 23, and 24 duplexes with 
dissociation temperatures labelled. 
3.2.1. Bipartate synthesis 
Progressing to the synthesis of the clinically relevant orientation of the ICL requires 
the design of a DNA duplex that is composed of a sequence with two units of asymmetry 
(Scheme 2.1, 3.9). Asymmetry is a prerequisite for the capability of forming a 
complimentary 5'-GXC-3' motif around the site of the ICL capable of WC hydrogen 
bonding, where X is any nucleotide. Coupling of a monophosphoramidite dimer containing 
a protected 3'-alcohol which is robust to the conditions of solid-phase synthesis is essential. 
Further constraints imposed are the need for facile removal with no degradation of the 
intermediate DNA duplex during deprotection. The bipartate strategy involves the 
formation of only one phosphorous linkage to a linear strand during coupling of the dimer. 
This offers the advantage over the monopartate approach of not requiring optimization of 
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the dimer concentration also allowing a higher concentration to further push the reaction to 
completion. 
Scheme 3.9 Synthesis of interstrand cross-link duplexes 27a (butyl) and 27b (heptyl). 
5' 5' 5' ! 
c c c c 
G G G G 
A A A A 
DMT DMT T T T T 
G —iG G ^ G G ^ G 
''A A Mix A AI|0C A T 
c . c .. c c c 
A ' A u A m > l v A A 
T "" T - T ~ T T 
c c c c c 
G G G G G 












c c G G 
A A 
T T 














G - ^ C 
A I T 




S.G C , 
27a, 27b 
(1,3-XL) 
Conditions: (i) The addition of 12a or 12b, (ii) followed by 3'-0-2'-
deoxyphosphoramidites, (iii) Pd(PPli3)4, PPh3, butylamine/formic acid (1:1) (iv) continued 
chain growth with 5'-0-2'-deoxyphosphoramidites, (v) cleavage from the solid-support and 
deprotection using 1:3 ethanol/ammonium hydroxide (28%). Nucleoside loading on CPG 
was 65 umol/g. 
The bipartate synthesis is begun in the same manner as the monopartate with the 
generation of a linear sequence. This is followed by coupling of a 3-0-
monophosphoramidite 12a or 12b in an off-column fashion to use only the required 
quantities of each dimer (Table 3.5). Dried dimers were added to separate screw-cap 
microfuge tubes with the L-sequence stationary phase. A tetrazole solution (0.45 M, 100 
uL) was added to the microfuge tubes to dissolve the dimers upon which the samples were 
left to react for 1 hour. In addition to NMR analysis providing an indication of the samples' 
purity (12a and 12b), the two solutions were clear in ACN at 0.200 M indicating minimal 
phosphoramidite side-products. After coupling the respective solid-supports were returned 
to DNA synthesis columns followed by a rinsing step using THF (30 mL) followed by 
ACN (30 mL). Samples were then placed under high vacuum for ~10 min to remove to 
residual solvents and then reinstalled on the DNA synthesizer to resume 3'-> 5' chain 
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extension to form the Y-sequence 17-mer 26a and 26b. A capping step is performed, 
aqueous iodine oxidation, then a detritylation step with TCA followed by continued chain 
growth using 3'-<9-phosphoramidite nucleotides. 
Table 3.5 Quantities of 3' and 5'-0-phosphoramidites required to generate 26a and 26b 




























































A variety of challenges were encountered during the syntheses of 26a and 26b with 
the failure to observe an orange coloured trityl cation when the reinstalled samples were 
treated with TCA. It was thought that failure to couple was the result of moisture or a 
contaminant in both syntheses using 12a and 12b. The presence of water can be expected 
to compete with the 5'OH of the support bound 25 as a nucleophile to displace the 
isopropyl amine of a phosphoramidite which is readily protonated in the presence of 
tetrazole. Water would be expected to have a greater rate of reaction than 25 resulting in 
greatly diminished yields of the desired duplexes. In an effort to dry the 
monophosphoramidites while also increasing sample purity, column chromatography was 
performed on 12a and 12b. All solvents contained TEA (1%) to prevent decomposition 
with the slightly acidic silanols present in silica gel. To further remove water from the 
system, all solvents and the final products were dried over sodium sulphate. Co-
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evaporations with anhydrous THF were problematic as both 12a and 12b tend to bump 
excessively leading to loss of material and unwanted manipulations of the sample. The 
purified sample was sealed in a flask in solution over sodium sulphate for more than 24 
hours (4°C) to remove any traces of water. NMR and TLC analysis showed an 
improvement in the purity however the presence of water (0.5 eqv.) at 2.86 ppm in acetone-
d,6 (from an ampoule) was unavoidable with drying conditions used. A second set of solid-
phase reactions were performed following the aforementioned procedure with the purified 
samples. The trityl cation was observed to elute from the DNA synthesizer columns upon 
reinstallation and treatment with TCA which was followed by continued 3'->5' extension 
of the free 5'OH groups. 
Subsequent chain growth in the 5'->3' direction necessitates the removal of the 
alloc group120'121 via an off-column method due to incompatibility of the DNA synthesizer 
to Pd(PPIi3)4. After the Y-sequence synthesis was completed the solid-support was 
removed from the DNA synthesizer and placed into 4 mL vials with Teflon septa. A 
solution (1 mL) consisting Pd(PPli3)4 in the presence of a 1:1 butylamine/formic acid from a 
stock solution emulsified in THF was prepared (Table 3.6). Equal portions (500 uL) of the 
parent solution were added to each 4 mL vial. The vials were then sealed with parafilm, 
wrapped in tin foil, and placed on a shaker at the lowest setting (30 rpm) overnight. It was 
observed that the solution which was originally pale yellow turned to black overnight, 
staining the solid support even after successive washings. Using a Pasteur pipette, CPG 
portions (~10 beads) were taken for NH40H/EtOH deprotection at 55 °C overnight. The 
oligonucleotides were then analyzed by SAX HPLC to confirm successful dimer couplings 
as indicated by a large ratio of Y-sequence to n-1 failure and pre-dimer linear sequences. 
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Significant challenges were also encountered with the stability of the solid support 
bound Y-sequence cross-link. Initially it was thought that the deprotection conditions 
(NH4OH/EtOH 3:1 overnight at 55°C) were responsible. Variation in time and temperature 
with additional solid-phase samples employed a 2 hour deprotection at room temperature 
and continued treatment for an additional 24 hours at 55°C of the previously analysed 
samples. No difference between samples deprotected for 2 hours or 48 hours were 
observed ruling out ammonia degradation. 
To confirm the point of decomposition another 1 umol scale solid-phase synthesis 
was conducted using 12a and 12b. The off-column coupling of 12a and 12b were 
successful as indicated by the trityl cation removal during TCA treatment. Analysis was 
performed before and after alloc deprotection demonstrating a dramatic change in sample 
composition with decomposition occurring during off-column Pd(PPli3)4 treatment (Figure 
3.6). This contrast from yields in solution phase deprotection can likely be explained by the 
decreased time of exposure to the Pd(PPli3)4 catalyst in addition to a dramatic increase in 
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Figure 3.6. Pre and post Pd(PPri3)4 alloc deprotection group of Y-sequences 26 using SAX 
In a desire to synthesize duplex 27b, the blackened solid-support was reinstalled on 
the DNA synthesizer after washing. Deprotected Y-sequence extension with normal V-O-
phosphoramidites demonstrated it was possible to generate the desired full-length product. 
The successful coupling of the more sterically congested 3'OH to a 3'-0-phosphoramidite 
also displayed the coupling times were sufficient for less strained 5'-0-phosphoramidite 
coupling at the site of the cross-link. Continued 5 ' - ^ 3 ' extension on the intact Y-sequence 
using 5'-(9-phosphoramidite nucleotides was performed followed by a final detritylation 
step. After the completed synthesis the black stained appearance of the solid-support had 
been removed. The solid-support was then deprotected overnight with NH4OH/EtOH (3:1) 
and analysed revealing the major component being 25, a minor population of n-1 failure 
sequences and 27b (Figure 3.7). Final analysis of the purified 27b showed a highly pure 
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sample suitable for further structural studies. Purified 27b was analyzed by SVPDE and calf 
intestine phosphatase digestion as described previously.14 MALDI-TOF indicated a 
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Figure 3.7. Analytical chromatograms using SAX HPLC of the crude synthesis of duplex 
27b and final purified product. 
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Figure 3.8 HPLC analysis of a snake venom phosphodiesterase and calf intestinal 
phosphatase digest of 27b using a Waters 1525 pump and 2487 detector using a Symmetry 
CI8 (4.6 x 150mm, 5um) column. 
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Table 3.7 Nucleoside composition ratios corrected for molar extinction coefficients and 
normalized to one for the cross-linked duplex 27b. MALDI-TOF: observed 6765.28 
(expected 6768.29) 
Nucleoside Peak area Nucleoside ratios 
Expected Observed 
dC 828094 1.50 1.53 
dG 882950 1.00 1.03 
dT 824288 1.25 1.24 
dA 1314029 1.25 1.25 
dG-dG 159606 0.25 0.25 
In light of the degradation observed for the synthesis of 27a and 27b using the alloc 
protecting group, consideration was given to its removal using the higher yielding solution 
phase reaction on dimer 10b to generate 13 which was then phosphitylated to yield 14. 
Slight modifications to solid phase synthesis protocols were explored as TBS deprotection 
with TEA-3HF is incompatible with controlled pore glass (CPG) and glass components on 
the DNA synthesizer. A polystyrene solid support was utilized with off-column 
deprotection of the Y-sequence and step iii deprotection conditions in Scheme 3.9 were 
replaced with TEA»3HF. Chromatograms of the post-deprotection yields using TEA*3HF 
on TBS and Pd(PPh3)4 on alloc were compared with respect to overall yield. Pre-
deprotection coupling yields on polystyrene were comparable to CPG yields. TEA»3HF 
removal of the 3'protecting group generated the most favourable results with no observable 
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Figure 3.9. SAX-HPLC chromatogram demonstrating improved yield from deprotection of 
3'TBS using TEA«3HF on a polystyrene solid-support. 
Previously published data on 24 serves to demonstrate the destabilizing effect that the 
mismatched 2'-deoxyguanosine base pairs exert as indicated by a 23 °C shift in dissociation 
temperature for 22.40 It should be noted that 22 only has one set of base pairs' hydrogen 
bonding disrupted in contrast to the two disrupted in 27b. Sufficient quantities of 27b were 
obtained from the initial alloc deprotection strategy to permit Tm and CD studies. 
Comparison of 27b (51.0°C) to its respective non-cross-linked control duplex 28 (50.0°C) 
indicates only a minimal increase in the stability of the duplex which is inside the range of 
experimental error (±1.0°C) (Figure 3.10). A sigmoidal denaturation curve qualitatively 
similar in shape to that of 28 was exhibited for 27b. Unlike 22 where control duplexes 24 
and to a lesser extent 23 have similar hyperchromicity profiles, the degree of 
hyperchromicity for 27b is 48% of 28 at each respective melting temperature. The lower 
net change in hyperchromicity suggests a significant amount of perturbation to the base 
stacking in 27b induced by the ICL and its disruption of two WC base pairings to a degree 
not present in 22. The near identical dissociation temperatures appears to be the result of 
the entropic stabilization of the two strands remaining unimolecular being balanced by 
destabilization from the disruption of WC base pairing induced by the presence of the 1,3-
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ICL. Evidence for the duplex destabilization and entropic effects balancing each other is 
displayed in the magnitude of hyperchromicity for 27b along side the dissociation 
temperature for 22 which supports this hypothesis. 
0.35 
S 
e 0.30 -1,3 C7 Duplex (27) 
-Native Duplex (28) 
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Temperature (°C) 
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Figure 3.10. UV thermal denaturation profile (A0.5°C/min) of the cross-linked (27b), non-
cross-linked control duplex (28) (5'-dCGATGACATCG)2. 
The CD spectra of 27b and 28 duplexes are displayed in Figure 3.11. Duplex 28 
exhibits a spectrum consistent with the signature of natural B-form DNA having its 
maximum at 281 nm, a minimum at 251 nm, and a crossover at 266 nm. The CD spectrum 
of 27b displays a degree of similarity with the general shape of the control duplex while 
having shift to lower frequencies for spectral features. The minimum of 27b is at 247 nm, 
the crossover at 261 nm, and the maxima at 278 nm. At low and high wavelength (<211 
and >290 nm) the molar ellipticities of 27b and 28 become convergent. The minimum of 
27b has a deviation from the signature pattern exhibited by the 28 having 0.48 times less 
molar ellipticity than 28 in this region. The contrasts to 22 showing 1.6 times greater molar 
ellipticity than its respective control 23 in its minimum area. The magnitude of the maxima 
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for 27b is 0.86 times the magnitude of 28 more closely approximating the relationship 
observed between 22 having 0.57 times less ellipticity than 23. These differences could 
result from changes in base stacking interactions induced from mismatched dG -dG in 22 
when compared to two dG*dC base pairs (where dG* is 06-alkylated). Modified duplexes' 
ability to transfer induced dipoles between bases when compared to their respective 
controls is a likely source of the observed divergences. The overall signature similarity of 
both 22 and 27b to that of their respective controls suggests the seven carbon ICL are well 
tolerated in both ICL duplexes. 
200 220 240 260 280 300 320 340 
Wavelength (nm) 
Figure 3.11 CD profile of the cross-linked oligonucleotide 27b and control duplex 28. 
3.2.2. Tripartate synthesis 
Advancement to the tripartate synthesis of 30 permits complete control over sequence 
composition around the cross-link (Scheme 3.10). It represents the highest degree of 
asymmetry in a DNA segment being reflected in many native DNA sequences. An 
additional complexity is introduced in that the tripartate dimer 19 has the 3' and both 5'-
alcohols orthogonally deprotected while still being compatible with solid-phase synthesis. 
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The potential exists for optimized drying and silyl deprotection methodologies from the 
bipartate strategy to be directly transferred to the tripartate synthesis. The tripartate strategy 
involves three off-column steps for the coupling of 19 to the linear sequence in step i, the 
5'-silyl deprotection in step iii, and the final removal of the 3'-levulinyl group in step v 
(Scheme 3.10). 
Scheme 3.10 Proposed stepwise synthesis of ICL duplex 30 using the tripartate strategy 
permitting complete asymmetry induction. 
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Conditions: (i) Off-column coupling of monophosphoramidite 19, (ii) chain growth with 3'-
0-2'-deoxyphosphoramidites, (iii) off-column TEA*3HF silyl deprotection (iv) continued 
chain growth with 3'-0-2'-deoxyphosphoramidites, (v) off-column hydrazine deprotection 
of the levulinyl group (vi) continued chain growth with 5'-0-2'-deoxyphosphoramidites, 
(vii) cleavage from the solid-support and deprotection using 1:3 ethanol/ammonium 
hydroxide (28%). A pre-packed 1 umol polystyrene column was used. 
The tripartate synthesis is begun in the same manner as the mono and bipartate 
strategies with the generation of a linear sequence. As in the bipartate methodology, this is 
followed by coupling of a 3-(9-monophosphoramidite 19 in an off-column fashion (Table 
3.8). Only one attempt was made at synthesizing duplex 30 which was performed 
concurrently with 27a and 27b. Once the L-sequence cycle had been completed the 
columns were removed from the DNA synthesizer. Vacuum dried 19 was added to separate 
screw-cap microfuge tube with the L-sequence stationary phase. A tetrazole solution (0.45 
M, 100 uL) was added to the microfuge tube to dissolve amidite 19 upon which the sample 
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was left to react for 1 hour. After reacting the solid-support was placed into DNA synthesis 
columns followed a rinsing step using a vacuum apparatus with THF (30 mL) followed by 
ACN (30 mL). The column was then placed under high vacuum for -10 min too remove to 
residual solvents and then placed on the DNA synthesizer to resume 3'-> 5' chain 
extension to form the Y-sequence product. Unfortunately during treatment with TCA no 
trityl cation was observed to elute from the column. As such the tripartate synthesis was 
not pursued until the optimized bipartate conditions could be applied. 
Table 3.8 Quantities required for solid-phase synthesis of ICL duplex 30 using 3'-0-



































* Solvent is ACN. 
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3.3 Molecular Modeling 
3.3.1 Comparison of Previous Modeling to Hyperchem Model for 1,3-ICL 
Orientations 
Initial studies by Colvin et. al. on the connectivity of the N7-N7-ICL formed by HM 
were complemented by molecular modeling to discern if the seven carbon chain would span 
the N7-N7 distance within a typical DNA duplex.24 Modeling studies in Macromodel (v.4.0) 
using AMBER force field with the GB/DA solvation demonstrated the heptyl alkyl linkage 
fitting into the major groove of DNA resulting in the generation of a slight wobble in the 
dG -dC base pairs.24 The length of a 1,7-diaminoheptane chain (9.8 A) was calculated to be 
sufficiently long to bridge the N7-N7 distance for a typical x-ray structure of a 5'-GXC-3' 
sequence (8.9 A) with minimal distortion in the DNA (Figure 3.12).24 Using a dodecamer 
(ACTAGGCCTAGT) ICL duplex, Colvin calculated the optimized N7-N7 distance to be 
8.05 A and the same unmodified duplex to be 9.25 A.24 These distances diverge from 
values obtained using Hyperchem modeling software (geometry optimized using the 
AMBER forcefield in vacuo) for an ICL sequence producing a shorter N7-N7 distance of 
6.41 A and the control duplex to be 8.64 A (Table 3.9). The Hyperchem model displays 
stronger correlation for N7-N7 distances for non-modified duplexes to typical of x-ray 
structures (Hyperchem: < 0.25 A, Colvin: > 0.35 A). The observed divergence in models is 
7 7 
greater when the degree of distortion for respective ICL duplexes are compared for N -N 
distances with Colvin's model (1.2 A closer) against the Hyperchem model (2.23 A closer) 
(Figure 3.13, 3.14, 3.15). It is possible that a Hyperchem model factoring in hydration 
effects could have a dramatic influence on the geometry of the phosphate backbone 
producing a stronger correlation between the two models, particularly in the ICL structures. 
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Overall the divergences in the geometry prediction between the two calculated models 
make direct comparison suspect. 
Figure 3.12 Theoretical model of the clinically relevant 1,3 JV'dG-heptyl-JV'dG cross-link 
lesion. The heptyl chain is outlined with a dashed black and white bond.24 
Figure 3.13 Control duplex 28. Only three base-pairs of the eleven base-pair duplex are 
shown for clarity. The calculated Oe-Oe distance is 6.41 A and the N1-N1 distance is 8.64 A 
7 7 
Figure 3.14. The \,3>-N dG-heptyl-JV dG duplex. Only three base-pairs of the eleven base-
pair duplex are shown for clarity. The heptyl chain is coloured green. The calculated 06-Oe 
distance is 5.47 A and the N7-N7 distance is 6.41 A 
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Figure 3.15. l,l-06dG-heptyl-06dG duplex 27b. Only three base-pairs of the eleven base-
pair duplex are shown for clarity. The heptyl chain is coloured green. The calculated O -
O6 distance is 5.76 A and the JV7-iV7 distance is 8.90 A. 
Table 3.9 Distances between shared reference point atoms for duplexes 27a, 27b, 28, and 





















The exact connectivity of the lesion formed by BU has to date not yet been discerned 
but it is theorized to form more intrastrand cross-links and a 1,3-lesion similar to HM.3 
7 7 
Molecular models were calculated for BU using the clinically relevant 1,3-N-N 
connectivity for HM and the 06-06 connectivity for duplex 27a. The shorter butyl linker in 
7 7 
a 1,3-lesion would not span the N -N distance inducing a larger amount of distortion from 
f\ ft 7 7 
the parent conformation for both 0-0 and to a much greater extent for N -N lesion 
models (Figure 3.13, 3.16, 3.17). As expected the l^-A^-dG-butyl-A^-dG lesion displays 
7 7 
the greatest amount of distortion from 28 as interbase distance displays the shortest N -N 
(5.95 A) while 27a displays the shortest 06-06 distance (5.03 A). This distortion in 27a 
would be expected to produce a larger departure from a B-form signature and would alter 
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the Tm profile to a when compared with data obtained for 27b. The larger distortion induced 
by a BU JV7-JV7 linkage could result in increased recognition and repair by a cell accounting 
for higher efficacy demonstrated by HM. 
Figure 3.16. l^-A^dG-butyl-A^dG duplex. Only three base-pairs of the eleven base-pair 
duplex are shown for clarity. The butyl chain is coloured green. The calculated O -0s 
distance is 5.32 A and the N -N1 distance is 5.95 A 
Figure 3.17. l,3-06dG-butyl-06dG duplex 27a. Only three base-pairs of the eleven base-
pair duplex are shown for clarity. The butyl chain is coloured green. The calculated 06-06 
distance is 5.03 A and the N7-N distance is 8.71 A 
3.3.2 Hyperchem Model for 1,1 Duplexes 
Molecular modeling was used to provide a comparative analysis for the possible 
structural effects produced by the presence of mismatched base pairs and chemically 
modified duplexes (Table 3.10, Figure 3.18, 3.19, 3.20). It can be seen that both the 
mismatched duplex 23 and ICL duplex 22 are expected to see a distortion from the parent 
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control duplex 24. Calculations predict an increase in the l^-A^-dA-A^-dA distance in 
opposing strands for both non-WC duplexes. The mismatch modification in 22 and 23 are 
seen to push the phosphate backbone apart and displace both 2'-deoxyguanosines in 
opposite directions out of planarity from normal base stacking geometry. It is unknown if 
the change in hydrogen bonding pattern from 22 to the non-modified bases of 23 has a 
similar affect on duplex Tm values. Both duplexes display a similar shift from planarity in 
the heterocyclic bases greatly distorting normal hydrogen bond geometry. Lastly it can be 
seen that the presence of the ICL of 22 induces a greater distance for both 06-dG-06-dG 
and N -dA-N -dA measurements. 

















Figure 3.18 dG-dC native control duplex 24. Only three base-pairs of the eleven base-pair 
duplex are shown for clarity. 06dG-A^dC distance is 4.74 A A^dA-A^dA distance is 8.68 A 
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Figure 3.19 dG-dG mismatch control duplex 23. Only three base-pairs of the eleven base-
pair duplex are shown for clarity. 06dG-06dG distance is 4.09 A 7V7dA -N7dA distance is 
8.75 A 
Figure 3.20 l,l-06dG-heptyl-06dG- mismatch duplex 22. Only three base-pairs of the 
eleven base-pair duplex are shown for clarity. 06dG-06dG distance is 4.74 A N7dA-N7dA 
distance is 9.02 A 
3.3.3. Ada-C Direct Repair SAR from NMR Model 
A closer examination of SAR results suggests that an 06dG-alkyl-06dG or HM ICL 
might be inaccessible to the active site nucleophile Cysl45 if the modified base remained 
stacked within the DNA duplex (Figure 1.10).82 The potential inability of an CAlG-alkyl-
O^dG BU or HM interstrand cross-linked 2'-deoxyguanosine to enter the active site of 
the enzyme could result in AGT's failure to recognize the lesion. Synthesis of a DNA 
segment containing a BU O^dG-alkyl-O^dG ICL of defined position and orientation could 
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offer insight into the ability of 06-BG to potentate BCNU via depletion of AGT while 
leaving BU toxicity unaffected. Length of the alkyl chains in BU and HM could also affect 
the pharmacokinetics of repair due to an increased ability of a longer HM chain to fit into 
the binding pocket of AGT. A BU or HM ICL could also act as an absolute block to AGT 
if the nucleobase was prevented from becoming fully extrahelical and thus not allowed to 
enter the active site of the enzyme resulting in transition state inhibition. Alternatively if 
alkyl transfer occurred the AGT protein would be covalently tethered to the DNA duplex. 
It is uncertain if alkylation of this type would allow for the conformation changes within 
AGT that typically facilitate a mechanism of dissociation from DNA thus allowing cellular 
recognition prompting proteolytic degradation of alkylated AGT. This inability to 
recognize the covalently linked enzyme coupled with an inability to degrade the tethered 
enzyme could trigger apoptosis. Resultantly synthesis of structures of defined structure, 
composition and sequence would allow for the systematic investigation of the clinical 
relevance these repair pathways to determine the role of 06-alkylation in the toxicity of BU 
andHM. 
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Chapter 4: Conclusions and Future Directions 
In summary, a synthetic methodology to prepare DNA duplexes containing an 
O dG-alkyl-06dG dimer amenable to the conditions of solid phase synthesis has been 
developed. The first monopartate dimer was incorporated into a one helical turn duplex 
processing an ICL of defined structure and sequence. Biophysical studies consisting of CD 
measurements which confirm 22 exists as B-form DNA and Tm studies illustrating the 
presence of the 1,1-ICL has a stabilizing effect of 12°C over 23 and 23°C over 24. 
Observed changes in hyperchromicity were minimal indicating the 1,1-lesion was well 
tolerated inducing little deformation from control duplex 23. Sufficient quantities were 
obtained to permit biological and NMR structural studies which are currently ongoing with 
collaborators. 
Synthesis of the bipartate dimer allowed for the incorporation of an additional unit 
of asymmetry around the site of the ICL in 27b permitting the synthesis of the clinically 
relevant orientation. Yields of 26b were low due to decomposition encountered with 
overnight Pd(PPli3)4 deprotection. It is likely that the order of magnitude increase in the 
amount of Pd(PPli3)4 along with longer reactions times were responsible for this 
observation. Reaction conditions using lower amounts of catalyst loading for shorter 
periods of time in argon atmosphere could be explored to remedy this problem. 
Progressing with 5'-0-phosphoramidites after deprotection on 26b yielded sufficient 
quantities of 27b which was isolated for biophysical characterization. Enzymatic digests 
demonstrated good agreement with observed versus expected composition. CD studies 
revealed 27b to be in B-form DNA conformation. Tm dissociation temperatures for 28 were 
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1°C lower than 27b which also showed reduced hyperchromicity (48%) reflective of a 
probable disruption to base stacking. 
Subsequent experiments resulted in a convenient route to circumvent decomposition 
observed with the removal of the alloc group during solid-phase synthesis. Previous alloc 
removal using solution phase chemistry resulted in high yields (90%) as such the alloc of 
10 was removed in place of TBS to yield 13 which was phosphitylated to yield 14. 
Deprotection conditions with TEA»3HF necessitated a change from a CPG to a polystyrene 
solid support. Analysis of samples before and after silyl deprotection demonstrated no 
decomposition of the oligonucleotide after TEA*3HF treatment. No further synthesis was 
performed on the TEA»3HF deprotected 26b as it is believed that the quantity of 25 present 
was due to moisture present in 14. Drying conditions require improvement for the bipartate 
phosphoramidite dimer as traces of water after overnight drying in THF with excess 
Na2SC>4 were observed by NMR before another synthesis will be attempted. Optimization 
of the drying of 14 could result in near quantitative yields common to coupling of 
commercially available phosphoramidites. 
After the synthesis of 26b is optimized using TEA»3HF deprotection, sufficient 
quantities of 27a and 27b can be synthesized for NMR and X-ray crystallographic 
structural studies. This will enable the possibility to discern the solution phase and solid 
state torsion angles about each DNA segment containing the 1,3-orientation of the ICL. 
Comparisons can be made between the amounts of distortion induced by the 4 versus 7 
carbon linkers. Enzymatic repair rates of ICL duplexes which have been incorporated into 
plasmids can then be correlated in SAR studies in terms of bending and helical unwinding 
versus enzymatic recognition and repair rates. 
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The final synthesis of the tripartate pre-amidite dimer was obtained in high yield 
permitting long term storage of the compound. Optimized bipartate silyl removal 
procedures offer the chance of method transfer to the tripartate synthesis of duplex 30. 
Preliminary deprotection tests display compatibility of all protecting groups with overnight 
levulinyl deprotection using hydrazine. The differential protection at all alcohol 
functionalities will permit stepwise addition of each nucleotide allowing for each chain to 
be unique. Enzymatic digest and MALDI-TOF analysis will be performed to confirm 
duplex composition. The completely asymmetric tripartate 1,3-duplex having 'sticky ends' 
will then be integrated into a DNA plasmid permitting repair studies. Studies are ongoing 
to determine the repair pathways involved in these lesions and their function as BU and HM 
mimics. 
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Chapter 5: Experimental 
General. 
Protected 2'-deoxyribonucleoside-CPG supports, 3'-0-(P-2-cyanoethyl-JY,./V''-diisopropyl)-
5 '-0-dimethoxytrityl-Af2-isobutyryl-2' -nucleotide and 3'-(>dimethoxytrityl-5'-(9-(P-2-
cyanoethyl-./V, N '-diisopropyl)-A^2-isobutyryl-2' -nucleotide phosphoramidites were 
purchased from Proligo, Inc. (Boulder, Colorado). All anhydrous solvents were bought 
from EMD Chemicals (Gibbstown, New Jersey). All deuterated solvents were acquired 
from Cambridge Isotope Laboratories, Inc. (Andover, MA). Solid phase oligonucleotide 
syntheses were carried out with 500 A pore size CPG solid support with a nucleoside 
loading of 65 umol/g or prepacked 1 umol polystyrene solid support for the synthesis of 
duplex 27b. Silica gel and aluminum backed TLC plates were purchased from Silicycle 
(Ville de Quebec, Quebec). All other chemicals were obtained from Sigma-Aldrich 
Chemical Company (Milwaukee, Wisconsin) and used as is. Strong anion exchange (SAX) 
HPLC was carried out using a Dionex DNA PAC PA-100 column (0.4 cm x 25 cm) 
purchased from Dionex Corp. (Sunnyvale, California) on a Waters Breeze HPLC system. 
Reversed phase HPLC was carried out using a Symmetry C-18 5 urn column (0.46 cm x 15 
cm) purchased from Waters Inc. (Milford, Massachusetts). Injected samples were 
monitored at 260 nm for analytical runs or 290 nm for preparative runs. Denaturing 
polyacrylamide gel electrophoresis was carried out on a 20 cm x 20 cm x 0.75 cm gel 
containing 20% acrylamide and 7 mol/L urea in TBE (89 mmol/L Tris. 89 mmol/L boric 
acid, and 0.2 mmol/L ethylenediaminetetraacetate buffered at pH 8.0). The running buffer 
was TBE. Oligonucleotides were detected by UV shadowing and developed with STAINS-
ALL™. MALDI-TOF mass spectra for oligonucleotides were conducted at the John 
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Hopkins University Mass Spectrometry Facility using a Voyager DE-STR MALDI-TOF 
instrument. ESI mass spectra for all small molecules were collected at the Department of 
Chemistry at McGill University using a Kratos MS25RFA mass spectrometer. NMR 
spectra (% 13C, and 31P) were recorded using a Varian INOVA 300 MHz spectrometer. 
Chemical shifts are relative to that of CDCI3, DMSO-d6, or Acetone -d6 (!H and 13C) as 
internal standard or H3PO4 (31P) as external standard. 
Oligonucleotide synthesis and purification. 
The cross-linked structures 22, 27a, 27b were assembled using an Applied Biosystems 
Model 3400 synthesizer according to standard cyanoethylphosphoramidite chemistry 
protocols.133 Respective control duplexes were assembled as individual linear chain 
sequences and annealed. Long chain alkylamine (LCAA) CPG was used as the solid 
support. The nucleoside phosphoramidites were diluted in anhydrous acetonitrile at a 
concentration of 0.10 mol/L for the 3'- and 5'-0-phosphoramidites. Assembly of the 
sequences was carried out as follows: (a) detritylation with 3% TCA in DCM; (b) 
nucleoside phosphoramidites coupling time of 120 sec for commercial phosphoramidites, 
180 sec coupling time for nucleoside phosphoramidites couplings after the installation of a 
dimeric nucleoside, and 600 sec for the monopartate dimer 8b using on-column methods; 
(c) capping with 1:1 (v/v) of phenoxyacetyl anhydride-2,6,lutidine-THF 1:1:8 (v/v/v. 
solution A) and 1-methyl-imidazole-THF 16:84 (w/v, solution B); (d) oxidation with 0.02 
mol/L iodine in THF-water-pyridine, 2.5:2:1. Prior to final analysis the 5'-terminal trityl 
groups were removed on the synthesizer. The oligomer-derivatized CPG was transferred 
from the reaction column to screw-capped microfuge tubes fitted with teflon lined caps and 
the protecting groups were removed by treatment with 1 mL of concentrated ammonium 
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hydroxide-ethanol (3:1) for 4h at 55°C. The cross-linked duplexes were purified by SAX 
HPLC with a 30mL linear gradient of sodium chloride in a buffer that contained 100 
mmol/L Tris (pH 7.8) in 10% ACN at a flow rate of 1.0 mL/min. The purified oligomers 
were then desalted using C-18 SEP PAK cartridges (Waters Inc.) as previously 
described.131 
Nuclease digestion and MALDI-TOF mass spectrometry 
The cross-linked oligomers (0.2 A260 unit) were characterized by digestion with a 
combination of SVPDE (0.28 unit) and calf intestinal phosphatase (5 units) in a buffer 
containing Tris (pH 8.1, 10 mmol/L) and magnesium chloride (2 mmol/L) as previously 
described.131 The resulting mixture of nucleosides was analyzed by reversed phase HPLC 
and the ratio of nucleosides determined. 
Thermal denaturation experiments 
Solutions of each crosslinked duplex, mismatched duplex, and control non-cross-linked 
duplexes were prepared in a buffer containing 90 mmol/L sodium chloride, 10 mmol/L 
sodium phosphate, 1 mmol/L EDTA, pH 7.0 to a final concentration of 2 uM. The molar 
extinction coefficients of the oligonucleotides and cross-linked duplexes were calculated 
using nearest-neighbor approximations.134 Samples were degassed in a vacuum centrifuge 
prior to thermal denaturation experiments run in a Cary 300 Bio UV-Vis spectrophotometer 
fitted with a thermostated sample holder and temperature controller. The absorbance at 260 
nm was monitored as the samples were heated from 5 to 90 °C at a rate of 0.5°C/min. 
Denaturation curves were generated by plotting the relative hyperchromicity, defined as (at 
- #5°c)/(a9o°c), where a, is the absorbance at temperature t, aye is the absorbance at the initial 
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temperature of 5°C, and a9o°c is the absorbance at the final temperature of 90°C, versus 
temperature. 
Circular dichroism (CD) spectroscopy 
Solutions of each crosslinked duplex, mismatched duplex, and control non-cross-linked 
duplexes were prepared in a buffer containing 90 mmol/L sodium chloride, 10 mmol/L 
sodium phosphate, 1 mmol/L EDTA, pH 7.0 to a final concentration of 2 uM. The samples 
were equilibrated for 5-10 min at 5°C, and their CD spectra were recorded on a Jasco J-700 
spectropolarimeter equipped with a NESLAB RTE-111 circulating bath. Spectra were 
collected at a rate of 100 nm/min with a bandwidth of 1 nm and sampling wavelength of 0.2 
nm using fused quartz cells (Hellma, 165-QS). The molar ellipticity was calculated from 
the equation [6] = 61 CI, where 6 is the relative ellipticity (mdeg), C is the concentration of 
the oligonucleotide (mol/L) and / is the path length of the cell (cm). The data was processed 
on a PC computer using software supplied by the manufacturer and transferred into 
Microsoft Excel for presentation. Each spectrum shown is the average of 5 scans. 
Molecular modeling studies 
Molecular models of l lbp duplexes (5'-dCGAAAGTTTCG-3')2 and (5'-
dCGATGACATCG-3')2 were performed as controls. Corresponding mismatched 2'-
deoxyguanosine at the underlined site (5'-dCGAAAGTTTCG-3')2 as well as 06dG-heptyl-
06dG interstrand cross-links linking 2 '-deoxy guano sine at underlined sites (5'-
dCGAAAGTTTCG-3')2 (XL 1-1), JV7dG-butyl-jV7dG, 7V7dG-heptyl-iV7dG, <96dG-butyl-
6>6dG and 06dG-heptyl-<96dG (5'-dCGATGACATCG-3')2 (XL 1,3) were built using 
HyperChem molecular modeling software. All duplexes were geometry-optimized using 
the AMBER forcefield. 
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Chemical synthesis 
Aliyl 1-BenzotriazolyI Carbonate (AllocOBt) : To a solution of 1-hydroxybenzotriazole 
(6.06 g, 39.6 mmol) and DIPEA (5.76 g, 44.6 mmol) in THF (30 mL) was added with 
vigorous stirring Alloc-Cl (5.12 g, 41.2 mmol) at room temperature. After 30 min, the 
resulting precipitates were removed by filtration and washed with THF (20 mL x 2). The 
filtrate and washings were collected and evaporated to give a solid that was loaded onto 
silica gel in CH2C12 and eluted furnishing the pure AllocOBt; mp 107-111 °C (7.09g, 81% 
yield) as a white powder; lR NMR (CDC13, CHCI3 as reference) 7.5-8.3 (m, 4H, Ar), 6.14 
(m, 1H , CH2CH=CH2), 5.4-5.7 (m, 2H, CH2CH=CH2), 5.07 (dt, 2H, J - 5.4 and 1.8 Hz, 
CH2CH=CH2). NMR spectrum was identical to the original Aldrich product. 
1-O-fert-Butyldimethylsilylbutanol : To a solution of 1,4-butanediol (31.53 g, 349.9 
mmol) and imidazole (2.40 g, 35.3 mmol) was added DCM (20 mL) and THF (10 mL) to 
form a homogeneous solution. ter/-Butyldimethylsilyl chloride (1.11 g, 7.35 mmol) was 
solvated in THF (10 mL) and added dropwise over 5 min and the reaction left overnight. 
The sample was rotary evaporated and an extraction performed using DCM and 5% sodium 
bicarbonate (x3) and dried over magnesium sulphate. The sample was purified via silica 
gel chromatography using hexanes:ethylacetate (20:0 -> 17:3) to yield a viscous liquid; 
0.734 g (48.9% yield); Rf (Si02): 0.35, hexanes:ethylacetate 4:1; !H NMR (DMSO-d6, 
DMSO as reference): 4.36 (t, 1H, OH); 3.62 (t, 2H, CH2); 3.34 (t, 2H, CH2); 1.39-1.59 (m, 
4H, CH2); 0.98 (s, 9H, SiC(CH3)3); 0.03 (s, 3H, SiCH3); -0.04 (s, 3H, SiCH3). 
1-0-ferf-ButyIdiphenyIsilylbutanol : To a solution of 1,4-butanediol (22.23 g, 246.7 
mmol) and imidazole (0.696 g, 10.2 mmol) was added THF (10 mL) to form a 
homogeneous solution. fert-Butyldiphenylsilyl chloride (0.519 g, 1.89 mmol) was 
91 
solvated in THF (10 mL) and added dropwise over 5 min and the reaction left overnight. 
The sample was rotary evaporated and an extraction performed using DCM and 5% sodium 
bicarbonate (x3) and dried over magnesium sulphate. The sample was purified via silica 
gel chromatography using hexanes:ethylacetate to yield a viscous liquid; 0.562 g (90.6% 
yield); Rf (Si02): 0.35, hexanes:ethylacetate 4:1; *H NMR (DMSO-d6, DMSO as reference): 
7.57-7.63 (m, 4H, Ar); 7.38-7.49 (m, 6H, Ar); 4.37 (t, 1H, OH); 3.64 (t, 2H, CH2); 3.36 (q, 
2H, CH2); 1.43-1.61 (m, 4H, CH2); 0.98 (s, 9H, SiC(CH3)3). 
1-0-ferfButyldiphenylsilyIheptanol : 1,7-heptanediol (1.75 g, 13.3 mmol) and imidazole 
(2.80 g, 41.1 mmol) was added to THF (10 mL) to form a homogeneous solution, tert-
Butyldiphenylsilyl chloride (3.46 g, 12.5 mmol) was added dropwise over 20 min to a 
vigorously stirred solution. A white precipitate was visible near the end of addition of tert-
butyldiphenylsilyl chloride after which the reaction left overnight. The sample was rotary 
evaporated to dryness and an extraction performed using DCM and 5% sodium bicarbonate 
(x3) and dried over magnesium sulphate. The sample was purified via silica gel 
chromatography using hexanes:ethylacetate to yield a viscous liquid; 2.57 g (52.2% yield); 
Rf (Si02): 0.25, hexanes:ethylacetate 4:1; lU NMR (DMS0-<4 DMSO as reference): 7.57-
7.63 (m, 4H, Ar); 7.38-7.49 (m, 6H, Ar); 4.37 (t, 1H, OH); 3.61 (t, 2H, CH2); 3.36 (t, 2H, 
CH2); 1.18-1.58 (m, 10H, CH2); 0.98 (s, 9H, SiC(CH3)3). 
iV2-phenoxyacetyl-2'-deoxyguanosine (1): 2'-deoxyguanosine monohydrate (11.73g, 18.7 
mmol) was coevaporated with anhydrous pyridine (2 x 50 mL) and then suspended in 
pyridine (90 mL) and placed in an icebath (20 min). Trimethylsilyl chloride (28.0 mL, 101 
mmol) was added via a syringe and the reaction stirred (1 h). Phenoxyacetyl chloride (6.6 
mL, 21.7 mmol) was added and stirred at room temperature (4 h). The sample was cooled 
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to 0°C and concentrated ammonium hydroxide (28%, 100 mL) was diluted with water (100 
mL) then added and allowed to stir (20 min). The sample was rotary evaporated and placed 
under high vacuum overnight. The sample was suspended in water (500 mL) and CH2CI2 
(100 mL), allowed to precipitate, and filtered (x2) to yield 4.03g (81.3% yield) of an light 
beige powder; TLC (10% MeOH/ CH2C12), Rf = 0.25, *H NMR (DMSO-d6, DMSO as 
reference): 11.93 (s, 1H, NH1), 11.87 (s, 1H, NH), 8.24 (s, 1H, H8); 7.29-7.37 (t, 2H, Ar); 
7.00-7.03 (m, 3H, Ar); 6.20 (dd, 1H, HI' , J= 6.7); 5.34-5.42 (d, 1H, H3'), 5.00 (t, 1H, 
H4'); 4.95 (s, 2H, PhOCH2CO); 4.37-4.43 (m, 1H, OH3'); 3.87-3.94 (m, 1H, OH5'); 3.43-
3.57 (dd, 2H, H5', H5"); 2.52-2.59 (m, 1H, H2'); 2.27-2.34 (m, 1H, H2"); 13C NMR 8 
61.50, 66.23, 70.51, 83.10, 87.80, 114.58, 120.48, 121.37, 129.58, 137.75, 147.22, 148.19, 
154.93, 157.61, 170.98. 
S'-O-dimethoxytrityl-A^-phenoxyacetyW-deoxyguanosine (2) : A solution of 1 (5.82 g, 
14.5 mmol) was coevaporated with anhydrous pyridine (3 x 30 mL) and then suspended in 
pyridine (50 mL), followed by the addition of dimethoxytrityl chloride (5.95 g, 17.4 mmol) 
at room temperature (16 h). Methanol (10 mL) and NH4OH (28%), 4 mL) were combined 
and added whereupon the solution became cloudy. The solution was then rotary evaporated 
to dryness and the crude taken up in DCM (50 mL) and washed twice with 5% sodium 
bicarbonate (50 mL). The organic layer was then dried over sodium sulphate, evaporated to 
dryness and then placed on high vacuum overnight followed by silica gel chromatography 
using DCM: methanol (100:0.8 -» 100:2.0) to yield a 8.88 g (87.1% yield) of an light 
yellow foam; Rf (Si02): 0.43, CH2Cl2:MeOH 10:1; 'H NMR (DMSO-J6, DMSO as 
reference): 11.82 (s, 1H, NH1), 11.78 (s, 1H, NH), 8.13 (s, 1H, H8); 7.14-7.34 (m, 12H, 
Ar); 6.94-7.04 (m, 3H, Ar); 6.74-6.84 (t, 3H, Ar); 6.26 (dd, 1H, HI ' , J= 6.3); 5.31-5.40 (d, 
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1H, H3'); 4.85 (d, 2H, PhOCH2CO); 4.36-4.42 (m, 1H, 0H3'); 3.93-4.00 (m, 1H, H4'); 
3.71 (s, 3H, OCH3); 3.69 (s, 3H, OCH3); 3.07-3.23 (dd, 2H, H5', H5"); 2.67-2.75 (m, 1H, 
H2'); 2.31-2.38 (m, 1H, H2"); 13C NMR 8 40.56, 55.28, 64.08, 66.98, 72.02, 83.96, 86.48, 
86.56, 113.21, 114.87, 121.62, 122.80, 126.98, 127.92, 128.18, 129.95, 130.09, 135.67, 
135.71, 137.59, 144.58, 146.50, 147.96, 155.62, 156.63, 158.57, 170.24. 
3'-0-alloxycarbonyl-5'-0-dimethoxytrityI-7V -phenoxyacetyl-2'-deoxyguanosine (3) : 
To a solution of compound 2 (2.15 g, 3.06 mmol) in anhydrous THF/pyridine (9:1) was 
added dimethylaminopyridine (catalyst) followed by allyl 1-benzotriazoyl carbonate (0.888 
g, 4.05 mmol) and the mixture was allowed to stir at room temperature for 24 h. The 
solvent was removed, and the crude taken up in DCM (50 mL) and washed twice with 5% 
sodium bicarbonate (50 mL). The organic layer was then dried over sodium sulphate and 
evaporated to near dryness, which was purified by silica gel column chromatography using 
DCM: methanol (100:0.5 -» 100:1.4) to yield an off-white foam 1.84 g (76.2% yield); Rf 
(Si02): 0.37, CH2Cl2:MeOH 20:1; *H NMR (CDC13, CH2C12 as reference): 11.79 (s, 1H, 
NH1), 8.99 (s, 1H, NH), 7.85 (s, 1H, H8); 7.35-7.44 (m, 4H, Ar); 7.18-7.35 (m, 9H, Ar); 
7.12 (t, 1H, Ar); 7.02 (dd, 2H, Ar); 6.82 (dd, 4H, Ar); 6.32 (dd, 1H, HI' , J= 6.0); 5.90-6.05 
(m, 1H, allyl); 5.31-5.40 (m, 2H, allyl); 4.44-4.50 (m, 1H, H3'); 4.69 (d, 2H, PhOCH2CO); 
4.67 (d, 2H, vinylCH2CO); 4.31-4.36 (m, 1H, H4'); 3.79 (s, 6H, OCH3); 3.35-3.51 (dd, 2H, 
H5', H5"); 2.83-2.88 (m, 1H, H2'); 2.64-2.70 (m, 1H, H2"); 13C NMR 5: 38.50, 55.51, 
63.30, 66.86, 69.24, 79.66, 81.68, 86.73, 86.83, 113.42, 115.10, 119.92, 123.29, 125.21, 
127.32, 128.03, 128.10, 129.39, 130.27, 131.31, 138.99, 139.68, 139.74, 146.54, 146.96, 
147.60, 154.48, 155.23, 156.56, 158.88, 169.89; MS (ESI), m/z (M + Na): calcd for 
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C43H4iN5OioNa+, 810.275, found 810.25; m/z (M - H): calcd for C43H40N5O10", 786.278, 
found 786.24. 
3'-0-tert-butyldimethylsilyl-5'-0-dimethoxytrityl-A^-phenoxyacetyl-2'-deoxy-
guanosine (9) : To a solution of compound 2, (1.73 g, 2.46 mmol) in anhydrous N',N'-
dimethylformamide was added imidazole (1.133 g, 16.64 mmol) followed by tert-
butyldimethylsilyl chloride (1.24 g, 8.23 mmol) and the mixture was allowed to stir at room 
temperature for 16 h. The solvent was removed, and the crude taken up in DCM (25 mL) 
and washed twice with 5% sodium bicarbonate (25 mL). The organic layer was then dried 
over sodium sulphate and evaporated to dryness, which was purified by silica gel column 
chromatography using hexanes:ethylacetate (5:1 -> 1:3) to yield 0.58 g (83.2% yield) of an 
off-white foam; Rf (Si02): 0.55, CH2Cl2:MeOH 10:0.8; *H NMR (DMSO-</6, DMSO as 
reference): 11.85 (s, 1H, NH1), 11.78 (s, 1H, NH), 8.19 (s, 1H, H8); 7.10-7.36 (m, 12H, 
Ar); 6.92-7.02 (m, 3H, Ar); 6.74-6.84 (t, 3H, Ar); 6.21 (dd, 1H, HI ' , J= 6.9); 4.85 (d, 2H, 
PhOCH2CO); 4.49-4.54 (m, 1H, H3'); 3.81-3.86 (m, 1H, H4'); 3.70 (s, 6H, OCH3); 3.05-
3.23 (dd, 2H, H5', H5"); 2.72-2.77 (m, 1H, H2'); 2.32-2.37 (m, 1H, H2"); 0.79 (s, 9H, 
SiC(CH3)3); 0.03 (s, 3H, SiCH3); -0.04 (s, 3H, SiCH3); 13C NMR 5 -4.60, -4.50, 18.15, 
25.91, 41.15, 55.42, 63.48, 67.19, 72.68, 83.83, 86.74, 87.14, 113.31, 115.10, 122.38, 
123.28, 127.14, 128.09, 128.14, 130.24, 135.74, 135.78, 137.16, 144.61, 146.28, 147.85, 
155.52, 156.55, 158.75, 169.67; MS (ESI), m/z (M + Na): calcd for C45H5iN508SiNa+, 
840.340, found 840.20; m/z (M - H): calcd for C45H5oN508Si", 816.343, found 816.43. 
3'- O- alloxycarbonyl- 5'- O- dimethoxytrityl- N - phenoxyacetyl- O - (4-tert-butyI 
diphenylsiloxybutyl)-2'-deoxyguanosine (4a) : To a solution 3 (5.374 g, 6.82 mmol) in 
anhydrous dioxane (40 mL) was added 1-tert-butyldiphenylsilylbutanol (1.968 g, 9.63 
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mmol), triphenylphosphine (2.55 g, 9.72 mmol) followed by diisopropylazodicarboxylate 
(1.89 g, 9.34 mmol) introduced in a dioxane solution (4.4 mL) dropwise. The solvent was 
evaporated after lh and the crude was taken up in DCM (50 mL) and washed twice with 
5% sodium bicarbonate (50 mL). The organic layer was then dried over magnesium 
sulphate, filtered and evaporated to a solid. Flash chromatography with a short column on 
the crude mixture (sample:silica, 1:3, w/w) loaded in dichloromethane (DCM) and eluted 
with hexanes results in nearly all of the product and non-polar reaction components being 
eluted in the first fraction leaving the majority of triphenylphosphine oxide on the column 
as confirmed by thin layer chromatography (TLC). The resulting sample was purified by 
silica gel column chromatography using hexanes :ethylacetate (19:1 -> 13:7). 
Triphenylphosphine oxide was precipitated from contaminated fractions with diethyl ether. 
The white solid removed by filtration and the diethyl ether portion evaporated and 
combined with non contaminated fractions to yield 5.16 g (78.9% yield) of a white foam; Rf 
(Si02): 0.67, hexanes:ethylacetate 2:3; lH NMR (DMSO-d6, DMSO as reference): 10.52 (s, 
1H, NH1), 8.36 (s, 1H, H8); 7.34-7.64 (m, 11H, Ar); 7.11-7.29 (m, 11H, Ar); 6.89-6.95 (m, 
3H, Ar); 6.65-6.74 (dd, 4H, Ar); 6.40 (dd, 1H, HI ' , J= 12); 5.84-5.98 (m, 1H, allyl); 5.20-
5.35 (m, 3H, allyl, H3'); 4.97-5.06 (m, 2H, CH2OAr); 4.50-4.64 (m, 4H, vinylCH2CO, 
PhOCH2CO); 4.18-4.24 (m, 1H, H4'); 3.70 (t, 2H, CH2OSi); 3.67 (s, 3H, OCH3); 3.66 (s, 
3H, OCH3); 3.46 (dd, 1H, H5'); 3.23-3.27 (m, 1H, H2'); 3.15 (dd, 1H, H5"); 2.58-2.63 (m, 
1H, H2"); 1.90 (q, 2H, CH2); 1.67-1.76 (m, 2H, CH2); 0.94 (s, 9H, SiC(CH3)3), 13C NMR 5: 
19.48, 25.68, 27.36, 29.29, 36.05, 55.64, 63.91, 65.07, 67.58, 68.07, 68.89, 79.13, 84.57, 
84.68, 86.25, 113.61, 113.68, 115.20, 118.54, 119.32, 121.64, 127.25, 128.32, 128.56, 
129.40, 129.56, 130.16, 130.28, 130.49, 132.15, 132.27, 132.73, 132.77, 132.80, 133.96, 
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134.16, 135.72, 136.15, 142.39, 145.56, 152.23, 153.08, 154.27, 158.63, 158.67, 158.71, 
160.94, 168.16; MS (ESI), m/z (M + Na): calcd for C63H67N50iiSiNa+, 1120.450, found 
1120.39; m/z (M - H): calcd for CesHeeNsOnSi", 1096.453, found 1096.41. 
3' - O - alloxycarbonyl - 5' - O - dimethoxytrityl - N - phenoxyacetyl - O -(7-tert-
butyldiphenyIsiloxyheptyl)-2'-deoxyguanosine (4b) : To a solution of 3 (3.48 g, 4.41 
mmol) in anhydrous dioxane (20 mL) was added 1-tertbutyldiphenylsilyloxyheptanol (1.80 
g, 4.86 mmol), triphenylphosphine (1.76 g, 6.71 mmol) followed by 
diisopropylazodicarboxylate (1.37 g, 6.46 mmol) introduced in a dioxane solution (1.6 mL) 
dropwise. The syringe was rinsed with dioxane (0.9 mL, x3) and added to the reaction 
mixture. The solvent was evaporated after lh and the crude was taken up in DCM (50 mL) 
and washed twice with 5% sodium bicarbonate (50 mL). The organic layer was then dried 
over magnesium sulphate, filtered and evaporated to a solid. Flash chromatography with a 
short column on the crude mixture (sample:silica, 1:3, w/w) loaded in dichloromethane 
(DCM) and eluted with hexanes results in nearly all of the product and non-polar reaction 
components being eluted in the first fraction leaving the majority of triphenylphosphine 
oxide on the column as confirmed by thin layer chromatography (TLC). The resulting 
sample was purified by silica gel column chromatography using a hexanes:ethylacetate 
gradient (19:1 -> 13:7). Triphenylphosphine oxide was precipitated from contaminated 
fractions with diethylether. The white solid removed by filtration and the diethylether 
portion evaporated and combined with non contaminated fractions to yield 3.08 g (61.9% 
yield) of a white foam; Rf (Si02): 0.67, hexanes:ethylacetate 2:3; 'H NMR (CDC13, CHCI3 
as reference): 8.68 (s, 1H, NH1); 8.10 (s, 1H, H8); 7.66-7.71 (m, 4H, Ar); 7.16-7.46 (m, 
18H, Ar); 7.01-7.10 (m, 3H, Ar); 6.79 (dd, 4H, Ar); 6.48 (dd, 1H, HI ' , 7 = 5.7); 5.89-6.04 
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(m, 1H, allyl); 5.30-5.46 (m, 2H, allyl); 4.47-4.52 (m, 1H, H3'); 4.78 (s, 2H, CH2OAr); 
4.67 (dt, 2H, vinylCH2CO); 4.59 (d, 2H, PhOCH2CO); 4.35-4.39 (m, 1H, H4'); 3.78 (s, 6H, 
OCH3); 3.67 (t, 2H, CH2OSi); 3.52 (dd, 1H, H5'); 3.41 (dd, 1H, H5"); 3.18-3.23 (m, 1H, 
H2'); 2.71-2.76 (m, 1H, H2"); 1.89 (q, 2H, CH2); 1.33-1.62 (m, 6H, (CH2)3); 1.06 (s, 9H, 
SiC(CH3)3); 13C NMR 5: 19.45, 25.77, 26.14, 27.36, 28.80, 29.25, 32.93, 38.36, 55.46, 
63.11, 64.08, 68.20, 69.14, 78.95, 84.30, 84.46, 86.99, 113.44, 115.17, 119.07, 119.75, 
122.54, 127.22, 128.16, 128.34, 128.57, 129.40, 129.56, 130.08, 130.30, 131.41, 132.27, 
132.73, 132.77, 132.80, 133.96, 134.16, 135.71, 135.75, 140.11, 144.66, 151.50, 152.66, 
154.43, 157.47, 158.81, 161.55; MS (ESI), m/z (M + Na): calcd for C66H73N50i1SiNa+, 
1062.497, found 1062.39; m/z (M - H): calcd for C66H72N50iiSi", 1138.500, found 
1138.43. 
3'- O- alloxycarbonyl- 5'- O- dimethoxytrityl- TV2- phenoxyacetyl- O6- (4-
hydroxybutyl)- 2'-deoxyguanosine (5a) : To a solution of 4a (5.15 g, 5.38 mmol) in 
anhydrous THF (10 mL) was added dropwise, 1M tetrabutylammonium fluoride (645 uL, 
6.45 mmol) and the solution was allowed to stir at room temperature for 30 min. On 
completion the reaction was concentrated, taken up in DCM (50 mL), washed twice with 
5% sodium bicarbonate (50 mL). The organic layer was then dried over sodium sulphate 
and evaporated to dryness, which was purified by silica gel column chromatography using 
hexanes:ethylacetate (60:40 -> 20:80) to yield 3.25 g (70.3% yield) of an off-white foam; 
Rf (Si02): 0.50, CH2Cl2:MeOH 10:1; *HNMR (DMSO-d6, DMSO as reference): 10.58 (s, 
1H, NH1), 8.41 (s, 1H, H8); 7.31-7.36 (m, 4H, Ar); 7.18-7.21 (m, 7H, Ar); 6.95-7.02 (m, 
3H, Ar); 6.71-6.81 (dd, 4H, Ar); 6.45 (dd, 1H, HI' , J= 6.9); 5.89-6.04 (m, 1H, allyl); 5.27-
5.41 (m, 3H, H 3 \ allyl); 4.87-5.15 (m, 2H, CH2OAr); 4.63-4.67 (dt, 2H, vinylCH2CO); 
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4.59 (d, 2H, PhOCH2CO); 4.53 (t, 1H, OH); 4.23-4.30 (m, 1H, H4'); 3.74 (s, 3H, OCH3); 
3.73 (s, 3H, OCH3); 3.44-3.55 (m, 3H, CH2OH, H5'); 3.26-3.35 (m, 1H, H5"); 3.20 (dd, 
1H, H2'); 2.57-2.69 (m, 1H, H2"); 1.90 (q, 2H, CH2); 1.56-1.68 (m, 2H, CH2); 13C NMR 5: 
25.88, 29.64, 36.04, 55.66, 61.08, 65.06, 67.72, 68.03, 68.89, 79.13, 84.57, 84.68, 86.24, 
113.61, 113.69, 115.20, 118.54, 119.32, 121.65, 127.27, 128.33, 130.18, 130.27, 130.44, 
132.70, 136.15, 142.37, 145.56, 152.24, 153.03, 154.27, 158.64, 158.67, 158.71, 161.02, 
168.11; MS (ESI), m/z (M + Na): calcd for C47H49N5OnNa+, 882.333, found 882.23; m/z 
(M - H): calcd for C47H48N5O11", 858.335, found 858. 39. 
3'- O- alloxycarbonyl- 5'- O- dimethoxytrityl- N - phenoxyacetyl- O - (7-
hydroxyheptyl)- 2'-deoxyguanosine (5b) : To a solution of 4b (1.352 g, 1.20 mmol) in 
anhydrous THF (10 mL) was added dropwise, 1M tetrabutylammonium fluoride (135 uL, 
1.35 mmol) and the solution was allowed to stir at room temperature for 30 min. On 
completion the reaction was concentrated, taken up in DCM (50 mL), washed twice with 
5% sodium bicarbonate (50 mL). The organic layer was then dried over sodium sulphate 
and evaporated to dryness, which was purified by silica gel column chromatography using 
hexanes:ethylacetate (60:40 -> 20:80) to yield 0.949 g (89.6% yield) of an off-white foam; 
Rf (Si02): 0.50, CH2Cl2:MeOH 10:1; *H NMR (DMSO-^, DMSO as reference): 10.55 (s, 
1H, NH1), 8.36 (s, 1H, H8); 7.23-7.33 (m, 4H, Ar); 7.10-7.20 (m, 7H, Ar); 6.88-6.98 (m, 
3H, Ar); 6.71 (dd, 4H, Ar); 6.40 (dd, 1H, HI' , J = 5.7); 5.85-6.00 (m, 1H, allyl); 5.31-5.39 
(m, 1H, H3'); 5.22-5.35 (m, 2H, allyl); 5.00 (t, 2H, CH2OAr); 4.60 (d, 2H, vinylCH2CO); 
4.52 (d, 2H, PhOCH2CO); 4.34 (s, 1H, CH2OH); 4.18-4.26 (m, 1H, H4'); 3.69 (s, 6H, 
OCH3); 3.42 (dd, 1H, H5'); 3.30-3.41 (m, 2H, CH2OH); 3.19-3.31 (m, 1H, H2'); 3.14 (dd, 
1H, H5"); 2.56-2.64 (m, 1H, H2"); 1.80 (q, 2H, CH2CH2OAr); 1.21-1.47 (m, 6H, (CH2)3); 
99 
UC NMR 5: 25.77, 26.14, 28.80, 29.25, 32.93, 38.36, 55.46, 63.11, 64.08, 68.20, 69.14, 
78.95, 84.30, 84.46, 86.99, 113.44, 115.17, 119.07, 119.75, 122.54, 127.22, 28.16, 128.34, 
130.08, 130.30, 131.41, 135.71, 135.75, 140.11, 144.66, 151.50, 152.66, 154.43, 15747, 
158.81, 161.55; MS (ESI), m/z (M + Na): calcd for C5oH55N5OiiNa+, 924.380, found 
924.37; m/z (M - H): calcd for C50H54N5O11", 900.382, found 900.36. 
l,4-{0 -[3'-0-alloxycarbonyl-5'-0-dimethoxytrityl-iV-phenoxyacetyl-2'-deoxy-
guanidyl]}-butane (6a) : To a solution of compound 5a (0.245 g, 0.285 mmol) in 
anhydrous dioxane (3.0 mL), triphenylphosphine (0.156 g, 0.595 mmol) and compound 3 
(0.223 g, 0.283 mmol) were added. Diisopropylazodicarboxylate (0.117 g, 0.580 mmol) 
was introduced in a solution of dioxane (0.25 mL). The syringe was rinsed with dioxane 
(0.25 mL, x2) and added to the reaction mixture. The solvent was evaporated after 14 h and 
the crude was taken up in DCM (50 mL), washed twice with 5% sodium bicarbonate (50 
mL). The organic layer was then dried over sodium sulphate and evaporated to dryness, 
which was purified by silica gel column chromatography using hexanes/ethylacetate (70:30 
-» 20:80) to yield 0.247 g (53.1% yield) of a white foam; Rf (Si02): 0.55, 
hexanes:ethylacetate 1:4; 1H NMR (CDCI3, CDCI3 as reference): 8.83 (s, 2H, NH); 8.04 (s, 
2H, H8); 7.15-7.47 (m, 20H, Ar); 6.98-7.15 (m, 6H, Ar); 6.74-6.87 (m, 8H, Ar); 6.49 (dd, 
2H, HI' , J= 5.7); 5.91-6.06 (m, 2H, allyl); 5.48-5.56 (m, 2H, H3'); 5.31-5.47 (m, 4H, 
allyl); 4.60-4.85 (m, 12H, PhOCH2CO, vinylCH2CO, CH2OAr); 4.34-4.42 (m, 2H, H4'); 
3.78 (s, 12H, OCH3); 3.54 (dd, 2H, H5'); 3.44 (dd, 2H, H5"); 2.96-3.08 (m, 2H, H2'); 2.70-
2.79 (m, 2H, H2"); 2.17 (s, 4H, CH2CH2OAr); MS (ESI), m/z (M + Na): calcd for 
C9oH88Nio02oNa+, 1651.607, found 1651.53; m/z (M - H): calcd for C9oH87Nio02o, 
1627.610, found 1627.34. 
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l,7-{0 -[3'-0-alIoxycarbonyl-5'-0-dimethoxytrityl-Af-phenoxyacetyl-2'-deoxy-
guanidyl]}-heptane (6b) : To a solution of compound 5b (0.279 g, 0.309 mmol) in 
anhydrous dioxane (3.0 mL), triphenylphosphine (0.164 g, 0.624 mmol) and compound 3 
(0.246 g, 0.313 mmol) were added. Diisopropylazodicarboxylate (0.124 g, 0.614 mmol) 
was introduced in a solution of dioxane (0.25 mL). The syringe was rinsed with dioxane 
(0.25 mL, x2) and added to the reaction mixture. The solvent was evaporated after 14 h and 
the crude was taken up in DCM (50 mL), washed twice with 5% sodium bicarbonate (50 
mL). The organic layer was then dried over sodium sulphate and evaporated to dryness, 
which was purified by silica gel column chromatography using hexanes/ethylacetate (70:30 
-» 20:80) to yield 0.343 g (66.3% yield) of an off-white foam; Rf (Si02): 0.50, 
hexanes:ethylacetate 1:4; lH NMR (CDC13, CDCI3 as reference): 8.67 (s, 2H, NH); 7.98 (s, 
2H, H8); 7.13-7.40 (m, 22H, Ar); 6.97-7.08 (m, 6H, Ar); 6.73-6.80 (m, 8H, Ar); 6.45 (dd, 
2H, HI' , 7 = 6.0); 5.88-6.03 (m, 2H, allyl); 5.44-5.53 (m, 2H, H3'); 5.28-5.44 (m, 4H, 
allyl); 4.60-4.85 (s, 4H, CH2OAr); 4.64-4.67 (dt, 4H, vinylCH2CO); 4.58 (d, 4H, 
PhOCH2CO); 4.30-4.38 (m, 2H, H4'); 3.76 (s, 12H, OCH3); 3.50 (dd, 2H, H5'); 3.39 (dd, 
2H, H5"); 2.95-3.06 (m, 2H, H2'); 2.67-2.75 (m, 2H, H2"); 1.91 (s, 4H, CH2CH2OAr); 
1.51 (s, 6H, (CH2)3); MS (ESI), m/z (M + Na): calcd for C93H94Nio02oNa+, 1693.654, found 
1693.3; m/z (M - H): calcd for C93H93Nio02o, 1627.657, found . 
l,4-{06-[5'-0-dimethoxytrityl-Ar2-phenoxyacetyl-2'-deoxyguanidyl]}-butane (7a) : To a 
solution of compound 6a (0.239 g, 0.147 mmol) in anhydrous THF (~3 mL) was added 
triphenylphosphine (14.6 mg, 0.056 mmol) and palladium (0) tetrakistriphenylphosphine 
(30.2 mg, 0.026 mmol). A stock solution (1:1) of butylamine (731.4 mg, 10.0 mmol) and 
formic acid (461.4 mg, lO.Ommol) was prepared. The butylamine/formic acid solution 
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(84.5 mg, 0.709 mmol) was suspended in THF (~1 mL) and added via syringe to a 
vigorously stirred solution which was allowed to stir at room temperature for 40 min. On 
completion the reaction was concentrated, taken up in DCM (25 mL), washed twice with 
5% sodium bicarbonate (20 mL). The organic layer was then dried over magnesium 
sulphate and evaporated to dryness and purified by silica gel column chromatography using 
hexanes:ethylacetate:ethanol (20:80:0 -> 20:80:6) to yield 0.182 g (84.5% yield) of an off-
white solid. !H NMR (CDC13, CDC13 as reference): 8.84 (s, 2H, NH); 8.05 (s, 2H, H8); 
7.15-7.47 (m, 22H, Ar); 6.96-7.14 (m, 6H, Ar); 6.77-6.86 (m, 8H, Ar); 6.67 (dd, 2H, HI' , J 
= 6.3); 4.79-4.87 (m, 2H, H3'); 4.63-4.76 (m, 6H, CH2OAr, 30H') 4.63 (d, 4H, 
PI1OCH2CO); 4.35-4.44 (m, 2H, H4'); 3.77 (s, 12H, OCH3); 3.32-3.70 (dd, 4H, H5\ H5"); 
2.49-2.80 (m, 4H, H2', H2"); 2.18 (s, 4H, (CH2)2); MS (ESI), m/z (M + Na): calcd for 
C82H8oNioOi6Na+, 1483.565, found 1483.33; m/z (M - H): calcd for CgiHygNioOie, 
1459.568, found 1459.49. 
l^-i^-IS'-O-dimethoxytrityl-A^-phenoxyacetyl-l'-deoxyguanidyllJ-heptane (7b) : To 
a solution of compound 6b (0.328 g, 0.196 mmol) in anhydrous THF (~3 mL) was added 
triphenylphosphine (20.0 mg, 0.076 mmol) and palladium (0) tetrakistriphenylphosphine 
(47.1 mg, 0.041 mmol). A stock solution (1:1) of butylamine (731.4 mg, lO.Ommol) and 
formic acid (461.4 mg, 10.0 mmol) was prepared. The butylamine/formic acid solution 
(100.5mg, 0.843mmol) was suspended in THF (~1 mL) and added via syringe to a 
vigorously stirred solution which was allowed to stir at room temperature for 40 min. On 
completion the reaction was concentrated, taken up in DCM (25 mL), washed twice with 
5% sodium bicarbonate (20mL). The organic layer was then dried over magnesium sulphate 
and evaporated to dryness and purified by silica gel column chromatography using 
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hexanes:ethylacetate:ethanol (20:80:0 -» 20:80:6) to yield 0.130 g (77.3% yield) of an off-
white solid; Rf (Si02): 0.70, ethylacetate; The organic phase from work-up (CH2Cl2/3% 
NaHCC>3 (aq.)) was dried over MgS04 followed by flash chromatography 
(hexanes/ethylacetate/ethanol, 1:4:0 •* 4:16:1). *HNMR (CDC13, CDCl3as reference): 8.88 
(s, 2H, NH); 8.06 (s, 2H, H8); 7.15-7.48 (m, 22H, Ar); 6.96-7.14 (m, 6H, Ar); 6.77-6.86 (m, 
8H, Ar); 6.69 (dd, 2H, HV,J= 6.3); 4.76-4.94 (m, 2H, H3'); 4.59-4.76 (m, 6H, CH2OAr, 
30H') 4.59 (d, 4H, PhOCH2CO); 4.25-4.34 (m, 2H, H4'); 3.77 (s, 12H, OCH3); 3.33-3.74 
(dd, 4H, H5\ H5"); 2.50-2.84 (m, 4H, H2\ H2"); 1.92 (s, 4H, CH2CH2OAr); 1.46-1.58; 
(m, 6H, (CH2)3); MS (ESI), m/z (M + Na): calcd for C85H86NioOi6Na+, 1525.612, found 
1525.48; m/z (M - H): calcd for C85H85NioOi6+, 1501.615, found 1525.53 
l,7-{06-[3'-0-([/^2-cyanoethyl-A^^V-diisopropyl]phosphoramidite)-5'-0-
dimethoxytrityl-7V2-phenoxyacety 1-2'-deoxyguanidyl]}-heptane (8b) : Compound 7b 
(0.100 g, 0.066 mmol) was dissolved in DCM (1.0 mL) and diisopropylethylamine (34.4 
mg, 0.201 mmol) followed by P-2-cyanoethyl-Ar,Ar,Ar',A^'-tetraisopropylphosphor-diamidite 
(59.8 uL, 0.198 mmol) were added. After 4 h the reaction was found to be 50% complete 
and additional diisopropylethylamine (24 mg, 0.140 mmol) followed by p-2-cyanoethyl-
A^Af'.iV'-tetraisopropylphosphordiamidite (39.4 mg, 0.131 mmol) were added. The 
reaction was quenched after 4h by the addition of DCM (25 mL) and the solution was 
extracted with sodium bicarbonate (5 %, 3 x 50 mL). The organic layer was dried over 
sodium sulphate and evaporated to afford the crude product which was precipitated from 
hexanes to yield 0.065 g (52.0% yield) of product as an off-white foam; Rf (Si02): 0.47, 
hexanes:ethylacetate:ethanol (10:10:1); !H NMR (acetone-^, acetone as reference): 9.29 (s, 
1H, NH); 8.20 (s, 2H, H8); 7.12-7.46 (m, 22H, Ar); 6.94-7.06 (m, 6H, Ar); 6.69-6.83 (m, 
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8H, Ar); 6.49 (dd, 2H, HI" , J= 6.6); 5.01-5.09 (m, 4H, CH2OAr); 4.94-5.03 (m, 2H, H3') 
4.54-4.61 (m, 4H, PhOCH2CO); 4.23-4.31 (m, 2H, H4'); 3.74 (s, 12H, OCH3); 3.46-3.68 
(dd, 1H, H5', H5"); 3.12-3.25 (m, 2H, H2'); 2.60-2.86 (m, 2H, H2",); 2.72 (t, 2H, 
NCH(CH3)2); 1.89 (s, 4H, CH2CH2OAr); 1.45-1.58 (m, 6H, (CH2)3); 1.08-1.28 (m, 12H, 
NCH(CH3)2); 31P NMR (121.3 MHz, acetone-d6, ppm) 8: 154.75, 154.97; MS (ESI), m/z 
(M + Na): calcd for C85H86NioOi6Na+, 1925.828, found 1926.5. 
1 - {O - [3' -0-alloxycarbony 1-5'-0-dimethoxytrityl-N -phenoxyacety 1-2'-deoxyguanidy 1]} 
-4-{06-[-3,-0-tertbutyldimethylsilyl-5,-0-dimethoxytrityI-7V2-phenoxyacetyl-2,-
deoxyguanidyl]}-butane (10a) : To a solution of compound 5a (1.699 g, 1.976 mmol) in 
anhydrous dioxane (15 mL), triphenylphosphine (0.810 g, 3.087 mmol) and compound 9 
(1.575 g, 1.926 mmol) were added. Diisopropylazodicarboxylate (0.642 g, 3.018 mmol) 
was introduced in a solution of dioxane (5 mL). The syringe was rinsed with dioxane (1 
mL, x2) and added to the reaction mixture. The solvent was evaporated after 14 h and the 
crude was taken up in DCM (50 mL) and washed twice with 5% sodium bicarbonate (50 
mL). The organic layer was then dried over magnesium sulphate and evaporated to dryness, 
which was purified by silica gel column chromatography using hexanes/ethylacetate (1:0 -^ 
1:5) to yield 2.07 g (63.1% yield) of a white foam; Rf (Si02): 0.45, CH2Cl2:MeOH 20:1; !H 
NMR (CDC13, CH2C12 as reference): 8.82 (s, 1H, NH); 8.78 (s, 1H, NH); 8.06 (s, 1H, H8); 
8.00 (s, 1H, H8); 6.67-7.45 (m, 22H, Ar); 6.94-6.09 (m, 6H, Ar); 6.64-6.80 (m, 8H, Ar); 
6.42 (dd, 2H, HI ' , HI", J= 5.7, J= 6.9); 5.86-6.02 (m, 1H, allyl); 5.43-5.51 (m, 1H, H3'); 
5.27-5.44 (m, 2H, allyl); 4.78 (s, 4H, CH2OAr); 4.71 (d, 4H, PhOCH2CO); 4.57-4.69 (m, 
2H, vinylCH2CO); 4.52-4.64 (m, 1H, H3'); 4.31-4.39 (m, 1H, H4'); 4.03-4.11 (m, 1H, 
H4'); 3.75 (s, 12H, OCH3); 3.30-3.56 (dd, 4H, H5', H5', H5", H5"); 3.00 (m, 1H, H2'); 
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2.62-2.76 (m, 2H, H2\ H2"); 2.38-2.49 (m, 1H, H2"); 2.13 (s, 4H, (CH2)2); 0.85 (s, 9H, 
SiC(CH3)3); 0.04 (s, 3H, SiCH3); 0.00 (s, 3H, SiCH3); 13C NMR 5 -4.69, -4.55, 18.08, 
25.50, 25.87, 38.16, 41.01, 53.57, 55.31, 63.61, 63.97, 67.22, 67.26, 68.10, 68.19, 68.98, 
69.14, 72.63, 77.35, 78.81, 84.20, 84.33, 84.40, 86.58, 86.83, 87.06, 113.25, 113.29, 
115.02, 118.89, 119.00, 119.47, 119.56, 119.72, 122.28, 126.98, 127.07, 127.95, 128.01, 
128.19, 128.23, 128.50, 128.59, 129.90, 130.15, 131.28, 132.03, 132.07, 132.15, 132.29, 
135.58, 135.61, 135.83, 135.87, 140.10, 140.32, 144.54, 144.68, 151.30, 151.38, 152.53, 
152.59, 154.28, 157.37, 157.42, 158.61, 158.66, 161.22, 161.27, 166.57; MS (ESI), m/z (M 
+ Na): calcd for C^HggNioOigSiNa*, 1681.672, found 1681.47; m/z (M - H): calcd for 
C92H97NioOi8Si", 1657.676, found 1657.60. 
1 - {O - [3'-0-alloxy carbony 1-5'-0-dimethoxytrity 1-7V -phenoxyacety 1-2'-deoxyguanidyl]} 
-7-{06-[3'-0-tert-butyldimethylsilyI-5'-0-dimethoxytrityl-iV2-phenoxyacetyl-2'-
deoxyguanidyl]}-heptane (10b) : To a solution of 5b (1.73 g, 1.92 mmol) in anhydrous 
dioxane (10.0 mL), triphenylphosphine (0.765 g, 2.91 mmol) and compound 9 (1.54 g, 1.88 
mmol) were added. Diisopropylazodicarboxylate (0.592 g, 2.78 mmol) was introduced 
dropwise in a solution of dioxane (3 mL). The syringe was rinsed with dioxane (1 mL, x2) 
and added to the reaction mixture. The solvent was evaporated after 30 min and the crude 
was taken up in DCM (50 mL), washed twice with 5% sodium bicarbonate (50 mL). The 
organic layer was then dried over sodium sulphate and evaporated to dryness, which was 
purified by silica gel column chromatography using hexanes/ethylacetate (1:0 -> 1:4) to 
yield 2.32 g (71.1% yield) of an off-white foam; Rf (Si02): 0.70, CH2Cl2:MeOH 10:1; xH 
NMR (DMSO-J6, DMSOas reference): 10.58 (s, 1H, NH); 10.53 (s, 1H, NH); 8.39 (s, 1H, 
H8); 8.35 (s, 1H, H8); 7.10-7.34 (m, 22H, Ar); 6.88-6.97 (m, 6H, Ar); 6.64-6.80 (m, 8H, 
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Ar); 6.40 (dd, 1H, HV,J= 6.0); 6.34 (dd, 1H, HI ' , J= 6.6); 5.85-6.00 (m, 1H, allyl); 5.31-
5.39 (m, 1H, H3'); 5.21-5.35 (m, 2H, allyl); 4.97-5.03 (m, 4H, PhOCH2CO); 4.61-4.72 (m, 
1H, H3'); 4.60 (d, 2H, vinylCH2CO); 4.34 (t, 4H, CH2OAr); 4.17-4.26 (m, 1H, H4'); 3.69-
3.77 (m, 1H, H4'); 3.68 (s, 12H, OCH3); 3.46 (dd, 1H, H5'); 3.10-3.32 (m, 4H, H2\ H5', 
H5"); 2.86-2.98 (m, 1H, H2'); 2.54-2.65 (m, 1H, H2"); 2.27-2.38 (m, 1H, H2'); 1.80 (s, 4H, 
CH2CH2OAr); 1.41; (s, 6H, (CH2)3); 0.78 (s, 9H, SiC(CH3)3); 0.00 (s, 3H, SiCH3); -0.05 (s, 
3H, SiCH3); 13C NMR 8 -4.62, -4.48, 18.16, 25.95, 26.09, 28.98, 29.33, 29.56, 29.90, 
38.27, 41.11, 55.39, 63.68, 64.04, 68.04, 68.09, 68.15, 68.23, 69.07, 72.74, 78.91, 84.25, 
84.39, 84.47, 86.65, 86.90, 87.15, 113.32, 113.37, 115.11, 119.04, 119.15, 119.65, 122.45, 
127.06, 127.14, 128.03, 128.08, 128.27, 128.31, 128.78, 129.99, 130.21, 131.35, 135.66, 
135.69 135.91, 135.95, 140.04, 140.24, 144.61, 144.74, 151.34, 151.41, 152.54, 152.61, 
154.36, 157.41, 157.47, 158.69, 158.74, 161.44, 161.48, 166.42; ; MS (ESI), m/z (M+ Na): 
calcd for C94Hio4NioOi8SiNa+, 1723.719, found 1724.46; m/z (M - H): calcd for 
C94H103NioOi8Si", 1699.723, found 1699.59. 
l-{06-[3'-0-aIloxycarbonyl-5'-0-dimethoxytrityl-7V2-phenoxyacetyl-2'-deoxyguanidyl 
]}-4-{06-[5'-0-dimethoxytrityl-A^-phenoxyacetyI-2'-deoxyguanidyl]}-butane (11a) : To 
a solution of compound 10a (0.492 g, 0.297 mmol) in anhydrous THF (3 mL) was added 
dropwise, 1M tetrabutylammonium fluoride in THF (0.327 uL, 0.327 mmol) and the 
solution was allowed to stir at room temperature for 30 min. On completion the reaction 
was concentrated, taken up in DCM (25 mL), washed twice with 5% sodium bicarbonate 
(25 mL). The organic layer was then dried over sodium sulphate and evaporated to dryness, 
which was purified by silica gel column chromatography using hexanes:ethylacetate (1:0 -> 
1:5) to yield 0.344 g (75.0% yield) of an off-white solid; Rf (Si02): 0.39, ethylacetate; !H 
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NMR (CDCI3, CH2Cl2as reference): 8.86 (s, 1H, NH); 8.80 (s, 1H, NH); 8.36 (s, 1H, H8); 
8.33 (s, 1H, H8); 7.12-7.43 (m, 22H, Ar); 6.96-7.08 (m, 6H, Ar); 6.74-6.82 (m, 8H, Ar); 
6.60 (dd, 1H, HI ' , J= 6.6); 6.46 (dd, 1H ,H1", / = 6.0); 5.88-6.02 (m, 1H, allyl); 5.43-5.52 
(m, 1H, H3'); 5.28-5.44 (m, 2H, allyl); 4.54-4.70 (m, 12H, H3', OH3\ CH2OAr, 
vinylCH2CO, PhOCH2CO); 4.31-4.39 (m, 1H, H4'); 4.17-4.26 (m, 1H, H4'); 3.77 (s, 12H, 
OCH3); 3.32-3.56 (dd, 4H, H5', H5"); 2.94-3.06 (m, 1H, H2'); 2.67-2.79 (m, 2H, H2', 
H2"); 2.56-2.67 (m, 1H, H2"); 2.15 (s, 4H, CH2CH2OAr); 13C NMR 5 14.32, 25.12, 38.19, 
40.75, 55.31, 60.52, 63.97, 64.24, 67.26, 68.06, 68.99, 72.65, 78.81, 84.19, 84.28, 84..32, 
86.52, 86.60, 86.83, 113.25, 113.30, 115.03, 118.88, 119.02, 119.59, 122.32, 122.40, 
126.99, 127.07, 127.97, 128.01, 128.19, 128.23, 129.79, 129.92, 130.15, 131.27, 135.58, 
135.61, 135.82, 135.89, 140.09, 140.49, 144.53, 144.71, 151.11, 151.35, 152.48, 152.57, 
154.29, 157.26, 157.33, 158.61, 158.66, 161.19, 161.25; MS (ESI), m/z (M + Na): calcd for 
C86H84NioOi8Na+, 1567.586, found 1567.37; m/z (M - H): calcd for CgeHssNicAg", 
1543.589, found 1543.52. 
l-{06-[3'-0-alloxycarbonyl-5'-0-dimethoxytrityl-iV2-phenoxyacetyl-2'-
deoxyguanidyI]}-7-{06-[5'-0-dimethoxytrityl-iV2-phenoxyacetyl-2'-deoxyguaiiidyl]}-
heptane (lib) : To a solution of compound 10b (2.30 g, 1.35 mmol) in anhydrous THF (5 
mL) was added drop wise, 1M tetrabutylammonium fluoride in THF (1.7 mL, 1.7 mmol) 
and the solution was allowed to stir at room temperature for 30 min. On completion the 
reaction was concentrated, taken up in DCM (25 mL), washed twice with 5% sodium 
bicarbonate (25 mL). The organic layer was then dried over sodium sulphate and 
evaporated to dryness and purified by silica gel column chromatography using 
hexanes:ethylacetate (1:0 -> 1:5) to yield 1.86 g (86.6% yield) of an off-white solid; Rf 
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(Si02): 0.30, CH2Cl2:MeOH (20:1); !H NMR (DMSO-d6, DMSO as reference): 10.59 (s, 
1H, NH); 10.56 (s, 1H, NH); 8.38 (s, 1H, H8); 8.35 (s, 1H, H8); 7.25-7.37 (m, 8H, Ar); 
7.11-7.24 (m, 14H, Ar); 6.90-6.99 (m, 6H, Ar); 6.67-6.82 (m, 8H, Ar); 6.36-6.47 (dd, 2H, 
HI', HI' , J = 6.9, J = 6.6); 5.88-6.03 (m, 1H, allyl); 5.24-5.42 (m, 4H, H3\ H3', allyl); 
5.00-5.11 (m, 4H, CH2OAr); 4.63 (d, 2H, vinylCH2CO); 4.46-4.60 (m, 5H, OH3', 
PhOCH2CO); 4.19-4.28 (m, 1H, H4'); 3.97-4.05 (m, 1H, H4'); 3.71 (s, 12H, OCH3); 3.49 
(dd, 1H, H5'); 3.08-3.42 (m, 4H, H2', H5\ H5", H5"); 2.84-2.96 (m, 1H, H2'); 2.55-2.66 
(m, 1H, H2"); 2.33-2.45 (m, 1H, H2"); 1.83 (s, 4H, CH2CH2OAr); 1.45; (s, 6H, (CH2)3); 
13C NMR 8: 26.12, 29.03, 29.23, 36.05, 55.65, 65.07, 67.71, 68.03, 68.89, 71.30, 79.12, 
84.26, 84.57, 84.71, 86.04, 86.24, 87.02, 113.69, 115.17, 118.41, 118.53, 119.32, 121.61, 
127.24, 128.33, 130.16, 130.31, 130.42, 132.70, 136.12, 136.15, 136.26, 136.29, 141.99, 
142.37, 145.56, 145.67, 152.24, 152.35, 153.04, 153.13, 154.28, 158.63, 158.68, 158.71, 
160.97, 161.00, 168.17 ; MS (ESI), m/z (M + Na): calcd for C89H9oNioOi8Na+, 1609.633, 
found 1609.46; m/z (M - H): calcd for C89H89NioOi8", 1586.716, found 1585.52. 
l-l^-P'-O-alloxycarbonyl-S'-O-dimethoxytrityl-A^-phenoxyacetyl-I'-
deoxyguanidyl]}-4-{06-[5'-0-dimethoxytrityl-7V2-phenoxyacetyI-2'-deoxyguanidyl-3'-
0-(P-2-cyanoethyl-AyV-diisopropyl)phosphoramidite]}-butane (12a) : Compound 11a 
(0.600 g, 0.388 mmol) was dissolved in THF (5.0 mL) and diisopropylethylamine (120 uL, 
0.582 mmol) followed by A^jV'-diisopropylamino cyanoethyl phosphoramidic chloride (130 
uL, 0.330 mmol). After 4 h the reaction was found to be 50% complete and additional 
diisopropylethylamine (60 mg, 0.352 mmol) followed by Af JV'-diisopropylamino 
cyanoethyl phosphoramidic chloride (110 uL, 0.330 mmol) were added. The reaction was 
quenched after 4 h by the addition of DCM (25 mL) and the solution was extracted with 
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sodium bicarbonate (5 %, 3 x 50 mL). The organic layer was dried over sodium sulphate 
and evaporated to afford the crude product which was precipitated from hexanes to yield 
0.661 g (88.0% yield) of product as an off-white foam. This material was chromatographed 
using silica gel with hexanes:ethylacetate and 1% TEA to give 0.130 g (19.2% yield) of a 
white foam; Rf (Si02): 0.47, hexanes:ethylacetate (1:1); *H NMR (acetone-^, acetone as 
reference): 9.43 (s, 1H, NH); 9.40 (s, 1H, NH); 8.25 (s, 2H, H8); 7.09-7.51 (m, 22H, Ar); 
6.96-7.04 (m, 6H, Ar); 6.70-6.84 (m, 8H, Ar); 6.53 (dd, 2H, HI' ,HI' , J= 6.3); 5.94-6.09 
(m, 1H, allyl); 5.52-5.61 (m, 1H, H3'); 5.26-5.46 (m, 2H, allyl) 5.04-5.15 (m, 4H, 
CH2OAr); 4.73-4.78 (m, 4H, PhOCH2CO); 4.68 (d, 2H, vinylCH2CO); 4.35-4.44 (m, 1H, 
H4'); 3.30-3.38 (m, 1H, H4'); 3.77 (s, 12H, OCH3); 3.33-3.74 (dd, 4H, H5\ H5', H5", 
H5"); 3.15-3.27 (m, 1H, H2'); 2.60-2.80 (m, 5H, H2', H2", H2", NCH(CH3)2); 2.16 (s, 4H, 
CH2CH2OAr); 1.13-1.24; (m, 12H, NCH(CH3)2); 31P NMR (121.3 MHz, acetone-^, ppm): 
149.2, 149.5; MS (ESI), m/z (M + Na): calcd for C95HioiNi2Oi9PNa+, 1767.694, found 
1767.37; m/z (M - H): calcd for C95HiooNi2Oi9P", 1743.697, found 1743.33. 
1 - {O6- [3' -0-alloxy carbony 1-5' -0-dimethoxy trity l-iV2-phenoxy acetyl-2' -
deoxy guanidyl]} -7- {O6- [5' -0-dimethoxy trity l-iV2-phenoxy acetyl-2' -deoxy guanidyl-3' -
0-(P-2-cyanoethyl-JV,AP-diisopropyl)phosphoramidite]}-heptane (12b) : Compound l ib 
(0.618 g, 0.389 mmol) was dissolved in THF (5mL) and diisopropylethylamine (120 uL, 
0.660 mmol) followed by iV.iV'-diisopropylamino cyanoethyl phosphoramidic chloride (130 
uL, 0.582 mmol) were added forming a precipitate after 5 minutes. The atmosphere was 
then exchanged with argon. The reaction was rotary evaporated after lh then solvated in 
DCM (25 mL) and extracted with sodium bicarbonate (5 %, 2 x 25 mL). The organic layer 
was dried over sodium sulphate and evaporated to afford the crude product which was 
109 
precipitated from hexanes and was filtered to yield 0.657g (97.3 % yield) of an off-white 
powder. This material was chromatographed using silica gel with hexanes :ethylacetate and 
1% TEA to give 0.168 g (24.1% yield) of a white foam; Rf (Si02): 0.27, 0.41 
hexanes:ethylacetate:TEA (5:1:1%); *H NMR (acetone-d^, acetone as reference): 9.38 (s, 
1H, NH); 9.34 (s, 1H, NH); 8.24 (s, 1H, H8); 8.23 (s, 1H, H8); 7.15-7.48 (m, 22H, Ar); 
6.96-7.09 (m, 6H, Ar); 6.70-6.85 (m, 8H, Ar); 6.53 (dd, 2H, H1',H1\ J= 6.6); 5.92-6.09 
(m, 1H, allyl); 5.49-5.64 (m, 1H, H3 \ H3\ allyl); 5.26-5.45 (m, 2H, allyl); 4.96-5.17 (m, 
4H, CH2OAr); 4.65-4.77 (d, 2H, vinylCH2CO); 4.53-4.64 (m, 5H, H3', PhOCH2CO); 4.18-
4.27 (m, 1H, H4'); 3.28-3.35 (m, 1H, H4'); 3.77 (s, 12H, OCH3); 3.34-3.74 (m, 4H, H2\ 
H5', H5", 0(CH2)2CN); 3.14-3.26 (m, 1H, H2'); 2.94 (t, 2H, NCH(CH3)2); 2.61-2.82 (m, 
2H, H2", H2"); 1.93 (s, 4H, CH2CH2OAr); 1.56; (s, 6H, (CH2)3); 1.13-1.24 (m, 12H, 
NCH(CH3)2); 31P NMR (121.3 MHz, acetone-</6, ppm): 149.2, 149.5; MS (ESI), m/z (M + 
Na): calcd for CggHjoyNuOigPNa^ 1809.741, found 1809.47; m/z (M - H): calcd for 
C98Hio6Ni2Oi9P", 1785.744, found 1785.33. 
l-{06-[3'-0-tert-Butyldimethylsilyl-5'-0-dimethoxytrityl-iV2-phenoxyacetyl-2'-
deoxyguanidyl]}-7-{06-[5'-0-dimethoxytrityl-iV2-phenoxyacetyI-2'-deoxyguanidyl]}-
heptane (13) : To a solution of compound 10b (0.522 g, 0.307 mmol) in anhydrous THF (3 
mL) was added triphenylphosphine (24.4 mg, 0.093 mmol) and palladium (0) 
tetrakistriphenylphosphine (35.2 mg, 0.030 mmol). A stock solution (1:1) of butylamine 
(731.4 mg, 10.0 mmol) and formic acid (461.4 mg, 10.0 mmol) was prepared. The 
butylamine/formic acid solution (78.7 mg, 0.66 mmol) was suspended in THF (~1 mL) and 
added via syringe to a vigorously stirred solution which was allowed to stir at room 
temperature for 40 min. On completion the reaction was concentrated, taken up in DCM 
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(25 mL), washed twice with 5% sodium bicarbonate (25 mL). The organic layer was then 
dried over sodium sulphate and evaporated to dryness and purified by silica gel column 
chromatography using hexanes:ethylacetate (1:0 -> 1:4) to yield 0.153 g (76.0% yield) of 
an off-white solid; Rf (Si02): 0.33 hexanes:ethylacetate (1:4); lH NMR (CHC13, CH2Cl2as 
reference): 8.76 (s, 1H, NH); 8.67 (s, 1H, NH); 8.03 (s, 1H, H8); 8.01 (s, 1H, H8); 7.14-
7.44 (m, 22H, Ar); 6.97-7.09 (m, 6H, Ar); 6.74-6.84 (m, 8H, Ar); 6.60 (dd, 1H, HI' , J = 
6.6); 6.43 (dd, 1H, HI ' , J= 6.4); 4.40-4.85 (m, 10H, H3', H3', PhOCH2CO, CH2OAr); 
4.17-4.26 (m, 1H, H4'); 4.05-4.14 (m, 1H, H4'); 3.77 (s, 6H, OCH3); 3.75 (s, 6H, OCH3); 
3.45 (dd, 1H, H5'); 3.00-3.38 (m, 3H, H5", H5', H5"); 3.21 (s, 1H, 3'OH); 2.56-2.83 (m, 
3H, H2', H2", H2'); 2.40-2.51 (m, 1H, H2"); 1.90 (s, 4H, CH2CH2OAr); 1.52; (s, 6H, 
(CH2)3); 0.86 (s, 9H, SiC(CH3)3); 0.86 (s, 6H, (CH3)2); 13C NMR 5: -4.63, -4.48, 18.15, 
25.88, 25.94, 26.08, 28.97, 29.31, 40.83, 41.11, 53.63, 55.37, 55.39, 63.67, 64.32, 68.03, 
68.11, 68.23, 72.73, 84.36, 84.47, 86.60, 86.65, 86.68, 87.15, 113.32, 114.78, 115.11, 
119.14, 119.20, 122.43, 122.53, 127.06, 128.04, 128.31, 129.58, 129.98, 130.02, 130.21, 
135.91, 135.96, 140.23, 140.42, 144.74, 144.79, 151.16, 151.34, 152.50, 152.54, 157.33, 
157.49, 158.69, 161.43, 166.52; MS (ESI), m/z (M + Na): calcd for C9iH10oNioOi6SiNa+, 




0-(P-2-cyanoethyl-JV,JV-diisopropyl)phosphoramidite]}-heptane (14) : Compound 13 
(0.142 g, 0.088 mmol) was dissolved in THF (1.3mL) and diisopropylethylamine (26 uL, 
0.150 mmol) followed by N, N'-diisopropylamino cyanoethyl phosphoramidic chloride (30 
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uL, 0.132 mmol) were added. After 1 h the reaction was found to be 50% complete and 
additional diisopropylethylamine (13 uL, 0.075 mmol) followed by iV,JV'-diisopropylamino 
cyanoethyl phosphoramidic chloride (15 uL, 0.066 mmol) were added whereupon a 
precipitate formed. The reaction was quenched after 2h by the addition of DCM (25 mL) 
and the solution was extracted with sodium bicarbonate (5 %, 3 x 50 mL). The organic 
layer was dried over sodium sulphate and evaporated to afford the crude product which was 
precipitated from hexanes to yield 0.138 g (86.3 % yield) of product as an off-white foam. 
Rf (Si02): 0.72, 0.83 hexanes:ethylacetate (5:1); *H NMR (acetone-^, acetone as 
reference): 9.31 (s, 1H, NH); 9.29 (s, 1H, NH); 8.21 (s, 1H, H8); 8.20 (s, 1H, H8); 7.37-
7.44 (m, 4H, Ar); 7.12-7.34 (m, 18H, Ar); 6.92-7.05 (m, 6H, Ar); 6.69-6.81 (m, 8H, Ar); 
6.48 (dd, 1H, HI ' , J= 6.0); 6.44 (dd, 1H, HI' , J= 6.3); 5.01-5.07 (m, 4H, ArOCH2); 4.91-
5.00 (m, 1H, H3'); 4.84-4.90 (m, 1H, H3'); 4.54-4.60 (m, 4H, PhOCH2CO); 4.24-4.31 (m, 
1H, H4'); 3.98-4.05 (m, 1H, H4'); 3.74 (s, 12H, OCH3); 3.30-3.71 (m, 8H, H5', H5", 
OCH2CH2CN); 3.13-3.24 (m, 2H, H2'); 2.96-3.12 (m, 2H, NCH(CH3)2); 2.57-2.63 (m, 1H, 
H2"); 2.42-2.47 (m, 1H, H2"); 1.80-1.98 (m, 4H, CH2CH2OAr); 1.51 (s, 6H, (CH2)3); 1.12-
1.23 (m, 12H, NCH(CH3)2); 0.85 (s, 9H, SiC(CH3)3); 0.07 (s, 3H, SiCH3); 0.02 (s, 3H, 
SiCH3); 31P NMR (121.3 MHz, acetone-J6, ppm): 154.76,154.56; MS (ESI), m/z (M + Na): 
calcd for CiooHii7Ni2Oi7PSi Na+, 1839.806, found 1840.47; m/z (M - H): calcd for 
CiooHn6Ni2Oi7PSi", 1815.903, found 1816.34. 
5'-6>-tert-Butyldiphenylsilyl-iV2-phenoxyacetyl-2'-deoxyguanosine (15) : To a solution 
of compound 1, (2.44 g, 6.08 mmol) in anhydrous iV',A '^-dimethylformamide (40 mL) was 
added imidazole (1.68 g, 24.7 mmol) followed by addition via a syringe of tert-
butyldiphenylsilyl chloride (2.48g, 9.03mmol) and the mixture was allowed to stir at room 
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temperature for 18 h. The reaction mixture taken up in ethylacetate (90 mL) and washed 
thrice with 5% sodium bicarbonate (90 mL) and back extraction performed twice. The 
organic layer was then dried over sodium sulphate and evaporated to dryness, which was 
dried onto celite then purified by silica gel column chromatography using CH2Cl2:MeOH 
(100:0.4 -> 100:1.4) to yield 2.80g (72.0% yield) of an off-white foam; Rf (Si02): 0.41, 
CH2Cl2:MeOH 10:1; JH NMR (CDC13, CHCI3 as reference): 11.90 (s, 1H, NH1), 9.45 (s, 
1H, NH), 7.94 (s, 1H, H8); 7.58-7.67 (m, 4H, Ar); 7.27-7.45 (m, 8H, Ar); 7.08 (t, 1H, Ar); 
6.99 (d, 2H, Ar); 6.31 (dd, 1H, KV,J= 6.3,); 4.67-4.79 (m, 3H, PhOCH2CO, H3'); 3.97-
4.04 (m, 1H, H4'); 3.80-3.90 (dd, 2H, H5', H5"); 2.70 (s, 1H, OH3'); 2.49-2.60 (m, 2H, 
H2', H2"); 1.03 (s, 9H, SiC(CH3)3); 13C NMR 8: 19.38, 27.08, 29.90, 40.94, 53.66, 64.32, 
67.10, 71.82, 83.97, 87.47, 114.98, 121.68, 122.98, 128.00, 128.03, 130.12, 132.92, 132.98, 
135.66, 135.76, 137.49, 146.61, 147.96, 155.71, 156.72, 170.25; MS (ESI), m/z (M + Na): 
calcd for Cs^NsOeSiNa*, 662.241, found 662.16; m/z (M - H): calcd for Ca^eNsOeSf, 
638.224, found 638.35. 
S'-O-Levulinyl-S'-O-tert-butyldiphenylsilyl-A^-phenoxyacetyl-l'-deoxyguanosine (16) : 
To a solution of compound 15, (2.09 g, 3.26 mmol) in anhydrous dioxane (25 mL) was 
added DCC (2.35 g, 11.38 mmol) and DMAP (0.20 g, 1.62 mmol). Levulinic acid (2.26 g, 
19.50 mmol) was added to a vigorously stirred solution and the mixture was allowed to stir 
at room temperature for 3 h. The reaction mixture was vacuum filtered and the solid rinsed 
with dioxane (4 mL, x2). The orange coloured solution was dried and taken up in DCM (70 
mL) and washed with 5% sodium bicarbonate (40 mL, x3). The organic layer was then 
dried over magnesium sulphate, filtered and evaporated to dryness, which was then purified 
by silica gel column chromatography using CH2Cl2:MeOH (100:0.5 -> 100:1.4) to yield 
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1.77g (73.8% yield) of an off-white foam; Rf (Si02): 0.54, CH2Cl2:MeOH 16:1; lH NMR 
(CDC13, CHCI3 as reference): 11.90 (s, 1H, NH1), 9.19 (s, 1H, NH), 7.88 (s, 1H, H8); 7.61-
7.64 (m, 4H, Ar); 7.27-7.45 (m, 8H, Ar); 7.10 (t, 1H, Ar); 7.00 (d, 2H, Ar); 6.27 (dd, 1H, 
HI', J= 5.4); 5.51-5.60 (m, 1H, H3'); 4.58-4.63 (m, 2H, PhOCH2CO); 4.18-4.24 (m, 1H, 
H4'); 3.79-3.91 (dd, 2H, H5', H5"); 2.55-2.85 (m, 6H, CH2, H2', H2"); 2.21 (s, 3H, CH3); 
1.06 (s, 9H, SiC(CH3)3); 13C NMR 8: 19.41, 27.10, 27.87, 28.09, 30.00, 38.03, 38.12, 
38.43, 64.10, 67.13, 75.00, 83.72, 85.41, 115.07, 122.13, 123.22, 128.05, 128.10, 130.20, 
132.61, 132.8, 135.60, 135.77, 137.06, 146.41, 147.83, 155.48, 156.56, 169.72, 172.39, 
206.68; MS (ESI), m/z (M + Na): calcd for C39H43N508SiNa+, 760.277, found 760.16; m/z 
(M - H): calcd for C^^NsOgSi", 736.281, found 736.32. 
l-{0 -[3'-0-alloxycarbonyl-5'-0-dimethoxytrityl-A^-phenoxyacetyl-2'-deoxyguanidyl]} 
-7-{06-[3'-0-levuIinyl-5'-0-tert-butyldiphenylsilyl-Ar2-phenoxyacetyl-2'-
deoxyguanidyl]}-heptane (17): To a solution of compound 5b (1.26 g, 1.40 mmol) and 
triphenylphosphine (2.33 g, 8.92 mmol) in anhydrous dioxane (5.0 mL) was added 16 (1.05 
g, 1.43 mmol). DIAD (0.453 g, 2.13 mmol) was added dropwise over 1 min via a syringe. 
The syringe was rinsed with dioxane (0.2 mL, x4) and the solution was allowed to stir at 
room temperature for 30 min. On completion the reaction was concentrated, taken up in 
DCM (25 mL) and washed with 5% sodium bicarbonate (25 mL, x3). The organic layer 
was then dried over sodium sulphate and evaporated to dryness, which was purified by 
silica gel column chromatography using hexanes:ethylacetate (1:0 -> 1:4) to yield 1.58g 
(70.4% yield) of an off-white solid; Rf (Si02): 0.50, CH2Cl2:MeOH, 20:1; !H NMR (CDC13, 
CH2C12 as reference): 8.75 (s, 1H, NH); 8.67 (s, 1H, NH); 8.03 (s, 1H, H8); 7.98 (s, 1H, 
H8); 7.59-7.67 (m, 4H, Ar); 7.13-7.45 (m, 20H, Ar); 6.97-7.09 (m, 6H, Ar); 6.72-6.81 (m, 
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4H, Ar); 6.60 (dd, 1H, HI' , J= 6.0); 6.45 (dd, J= 6.3, 1H, HI"); 5.87-6.03 (m, 1H, allyl); 
5.53-5.59 (m, 1H, H3'); 5.43-5.52 (m, 1H, H3'); 5.27-5.44 (m, 2H, allyl); 4.76 (s, 4H, 
CH2OAr); 4.65 (d, 2H, vinylCH2CO); 4.58 (t, 4H, CH2OPh); 4.32-4.37 (m, 1H, H4'); 4.16-
4.22 (m, 1H, H4'); 3.81-4.01 (dd, 2H, H5', H5"); 3.76 (s, 6H, OCH3); 3.36-3.54 (dd, 2H, 
H5\ H5"); 2.95-3.05 (m, 1H, H2'); 2.56-2.85 (m, 7H, H2', H2", H2", (CH2)2); 2.18-2.23 
(m, 3H, CH3); 1.86-1.94 (m, 4H, CH2CH2OAr); 1.66; (s, 2H, (CH2)); 1.42-1.58; (m, 6H, 
(CH2)3); 1.06 (s, 9H, SiC(CH3)3); 13C NMR 8 19.32, 25.96, 27.02, 28.06, 28.85, 29.19, 
29.89, 37.98, 38.13, 38.53, 55.26, 63.92, 64.28, 67.95, 68.04, 68.93, 75.12, 78.78, 83.89, 
84.15, 84.28, 85.42, 86.78, 113.25, 114.98, 118.86, 118.93, 119.51, 122.33, 127.02, 127.91, 
127.96, 128.15, 129.45, 129.88, 130.01, 130.10, 131.24, 132.60, 132.83, 135.51, 135.57, 
135.67, 139.64, 139.93, 144.50, 151.29, 151.33, 152.49, 152.56, 154.23, 157.30, 158.62, 
161.37, 16.35, 172.29, 206.41; MS (ESI), m/z (M + Na): calcd for C89H96NioOi8SiNa+, 




(18) : To a solution of compound 17 (0.348 g, 0.214 mmol) in anhydrous THF (2.5 mL) 
was added triphenylphosphine (17.6 mg, 0.067 mmol) and palladium (0) 
tetrakistriphenylphosphine (36.9 mg, 0.032 mmol). A stock solution (1:1) of butylamine 
(731.4 mg, 10.0 mmol) and formic acid (461.4 mg, lO.Ommol) was prepared. The 
butylamine/formic acid solution (0.113 g, 0.952 mmol) was suspended in THF (~1 mL) and 
added via syringe to a vigorously stirred solution which was allowed to stir at room 
temperature for 40 min. On completion the reaction was concentrated, taken up in DCM 
115 
(25 mL) and washed with 5% sodium bicarbonate (25 mL, x3). The organic layer was then 
dried over sodium sulphate and evaporated to dryness and purified by silica gel column 
chromatography using hexanes:ethylacetate (1:0 -> 1:5) to yield 0.229 g (69.5% yield) of 
an off-white solid; Rf (Si02): 0.47, CH2Cl2:MeOH, 10:1; 'H NMR (DMSO-<4, DMSO as 
reference): 10.59 (s, 1H, NH); 10.57 (s, 1H, NH); 8.34 (s, 1H, H8); 8.33 (s, 1H, H8); 7.50-
7.58 (m, 4H, Ar); 7.14-7.42 (m, 19H, Ar); 6.84-6.97 (m, 6H, Ar); 6.66-6.88 (dd, 4H, Ar, J = 
9.0); 6.33-6.43 (dd, 2H, H1',H1', J= 6.3); 5.44-5.52 (m, 1H, H3'); 5.28-5.37 (d, 1H, H3'); 
4.99-5.04 (m, 4H, CH2OAr); 4.44-4.58 (m, 5H, PhOCH2CO, 30H'); 4.11-4.19 (m, 1H, 
H4'); 3.94-4.01 (m, 1H, H4'); 3.78-3.96 (dd, 2H, H5'); 3.69 (s, 6H, OCH3); 3.10-3.32 (m, 
3H, H2\ H5', H5"); 2.81-2.90 (m, 1H, H2'); 2.76 (t, 2H, CH2COCH3); 2.52 (t, 2H, 
CH2C02) 2.28-2.39 (m, 1H, H2"); 2.12 (s, 3H, COCH3); 1.80 (s, 4H, CH2CH2OAr); 1.41 
(s, 6H, (CH2)3), 0.93 (s, 9H, SiC(CH3)3); 13C NMR 5: 19.44, 25.01, 26.11, 27.28, 28.46, 
29.02, 29.20, 30.26, 36.32, 36.95, 38.17, 55.66, 64.80, 65.09, 67.63, 68.02, 71.30, 74.93, 
84.28, 85.49, 86.04, 87.02, 113.69, 115.17, 118.41, 121.59, 127.21, 128.36, 128.44,128.54, 
130.14, 130.31, 130.41, 130.54, 131.85, 131.98, 133.35, 133.47, 135.69, 136.25, 136.29, 
142.00, 145.66, 152.35, 152.45, 153.12, 153.20, 158.62, 158.67, 160.96, 161.01, 168.23, 
172.64, 207.54; MS (ESI), m/z (M + Na): calcd for Cgs^NioOieSiNa4, 1559.635, found 
1559.38; m/z (M - H): calcd for CgsHgiNioOieSi", 1535.639, found 1535.52. 
l-IO^P'-O-levulinyl-S'-O-tert-butyldiphenylsilyl-A^-phenoxyacetyW-
deoxyguanidyl]}-7-{0 - [(5'-0-dimethoxytrityl-iV -phenoxyacetyI-2'-deoxyguanidyl-3'-
0-(/^2-cyanoethyl-iV,AP-diisopropyl)phosphoramidite]}-heptane (19) : Compound 18 
(0.220 g, 0.143 mmol) was dissolved in THF (1.5 mL) and diisopropylethylamine (43 uL, 
0.243 mmol) followed by iV,7V'-diisopropylamino cyanoethyl phosphoramidic chloride (48 
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uL, 0.215 mmol) were added. After 1 h the reaction was found to be 50% complete and 
additional diisopropylethylamine (22 uL, 0.122 mmol) followed by iV.iV'-diisopropylamino 
cyanoethyl phosphoramidic chloride (24 uL, 0.107 mmol) were added whereupon a 
precipitate formed. The reaction was quenched after 2h by the addition of DCM (10 mL) 
and the solution was extracted with sodium bicarbonate (5 %, 3 x 10 mL). The organic 
layer was dried over sodium sulphate and evaporated and silica gel chromatography 
performed using hexanes:ethylacetate (1:0 -> 1:4) and TEA (1%) to yield 0.145 g (58.3% 
yield) of an off-white foam. Rf (Si02): 0.38, 0.50, hexanes:ethylacetate:TEA (1:4:1%); 'H 
NMR (CDC13, CHCI3 as reference): 10.58 (s, 1H, NH); 10.53 (s, 1H, NH); 8.36 (s, 1H, H8); 
8.33 (s, 1H, H8); 7.08-7.33 (m, 20H, Ar); 6.86-6.96 (m, 6H, Ar); 6.64-6.78 (m, 8H, Ar); 
6.33-6.43 (dd, 2H, H1',H1', J = 6.3); 5.15-5.24 (m, 2H, H3', H3'); 4.97-5.03 (m, 4H, 
PhOCH2CO); 4.46-4.55 (m, 5H, OH3', CH2OAr); 4.18-4.26 (m, 1H, H4'); 3.93-4.00 (m, 
1H, H4'); 3.67 (s, 12H, OCH3); 3.46 (dd, 1H, H5'); 3.03-3.32 (m, 4H, H2', H5\ H5"); 
2.82-2.91 (m, 1H, H2'); 2.55-2.64 (m, 1H, H2"); 2.36-2.42; (m, 2H, NCH(CH3)2); 2.28-
2.36 (m, 1H, H2"); 1.80 (s, 4H, CH2CH2OAr); 1.41; (s, 6H, (CH2)3) 1.14-1.25; (m, 12H, 
NCH(CH3)2); 31P NMR 8: 154.56, 154.76 MS (ESI), m/z (M + Na): calcd for 
C94Hio9Ni2Oi7PSiNa+, 1759.743, found 1759.47; m/z (M - H): calcd for Cg^iosN^OnPSi", 
1735.747, found 1735.53. 
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